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Chapter 1: Introduction and aims of present studies 
 
Neuropathic pain (NP) is a major symptom which may be 
intractable in common neurological disorders such as 
neuropathy, spinal cord injury, multiple sclerosis and 
stroke. Pain is a complex sensation strongly modulated by 
cognitive influences, and understanding the underlying 
pathophysiological mechanisms in patients remains a 
challenge for pain specialists.  The aim of my Phd-research 
was to show in according  with present evidence-based 
studies the correlation between clinical manifestations of 
neuropathic pain and the  underlying alteration of the 
different groups of fibers (Aβ, Aδ or C).  
 
In the second chapter I revised the previous guidelines 
about neuropathic pain assessment. History and clinical 
examination are a requirement to confirm the presence of a 
NP, and also an important step in reaching an aetiological 
diagnosis for NP. History and bedside examination are still 
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fundamental to a correct diagnosis, while screening tools 
and questionnaires are useful in indicating probable NP. I 
argued in particular a  recent technique, skin biopsy; I 
approached it at the beginning of my Phd during my stage 
at the I.R.C.S.S. C. Besta in Milan; then, I  imported this 
procedure  in our laboratory (Department of  Pathological 
Anatomy, Sapienza University). We are now able to 
process skin biopsies and immunoassayed them with 
polyclonal anti-protein-gene-product 9.5 antibodies 
(specific for nerve fibers) using immunohistochemistry or 
immunofluorescence, which allowed demonstrating the 
extensive innervations of the epidermidis. 
 
In the following chapters I approached  some common  
conditions of neuropathic pain. 
 
The third chapter is dedicated to the post-herpetic 
neuralgia, an exceptionally drug-resistant neuropathic 
pain. To investigate the pathophysiological mechanisms 
underlying postherpetic neuralgia we clinically 
investigated sensory disturbances, pains and itching, with 
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an 11-point numerical rating scale in 41 patients with 
ophthalmic postherpetic neuralgia. In all the patients we 
recorded the blink reflex, mediated by non-nociceptive 
myelinated Aβ-fibers, and trigeminal laser evoked 
potentials (LEPs) related to nociceptive myelinated Aδ- 
and unmyelinated C-fiber activation. We also sought 
possible correlations between clinical sensory disturbances 
and neurophysiological data. Neurophysiological testing 
yielded significantly abnormal responses on the affected 
side compared with the normal side. The blink reflex delay 
correlated with the intensity of paroxysmal pain, whereas 
the Aδ- and C-LEP amplitude reduction correlated with 
the intensity of constant pain . Allodynia correlated with 
none of the neurophysiological data. Our study shows that 
postherpetic neuralgia impairs all sensory fiber groups. 
The neurophysiological-clinical correlations suggest that 
constant pain arises from a marked loss of nociceptive 
afferents, whereas paroxysmal pain is related to Aβ-fiber 
demyelination. These findings might be useful for a better 
understanding of pain mechanisms in postherpetic 
neuralgia. 
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In the fourth chapter I treated the differential involvement 
of Aδ and Aβ fibers in neuropathic pain related to carpal 
tunnel syndrome (CTS). We studied 70 patients with a 
diagnosis of CTS (117 CTS hands). We used the DN4 
questionnaire to select patients with neuropathic pain, and 
the Neuropathic Pain Symptom Inventory (NPSI) to assess 
the intensity of the various qualities of neuropathic pain. 
All patients underwent a standard nerve conduction study 
(NCS) to assess the function of non-nociceptive Aβ-fibres, 
and the cutaneous silent period (CSP) after stimulation of 
the IIIrd and Vth digits, to assess the function of 
nociceptive Aδ-fibres. In 40 patients (75 CTS hands) we 
also recorded LEPs in response to stimuli delivered to the 
median nerve territory and mediated by nociceptive Aδ-
fibres. We sought possible correlations between 
neurophysiological data and the various qualities of 
neuropathic pain as assessed by the NPSI. We found that 
the median nerve sensory conduction velocity correlated 
with paroxysmal pain and abnormal sensations, whereas 
LEP amplitude correlated with spontaneous constant pain. 
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Our findings suggest that whereas paroxysmal pain and 
abnormal sensations reflect demyelination of non-
nociceptive Aβ-fibres, spontaneous constant pain arises 
from damage to nociceptive Aδ-fibres. 
 
In the fifth chapter I treated the  mechanisms of pain in 
multiple sclerosis. In this clinical and neurophysiological 
study we sought information on the clinical characteristics 
and underlying mechanisms of neuropathic pain related to 
the disease. A total of 302 consecutive patients with 
multiple sclerosis were screened for neuropathic pain by 
clinical examination and the DN4 tool. In patients selected 
for having ongoing extremity pain or Lhermitte’s 
phenomenon, we recorded somatosensory evoked 
potentials, mediated by Aβ non-nociceptive fibres, and 
LEP, mediated by Aδ nociceptive fibres. Of the 302 
patients, 92 had pain (30%), and 42 (14%) neuropathic pain. 
Patients with neuropathic pain had more severe multiple 
sclerosis, as assessed by the expanded disability severity 
score, than those without pain. Whereas in patients with 
ongoing neuropathic pain laser evoked potentials were 
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more frequently abnormal than somatosensory evoked 
potentials we found the opposite in patients with 
Lhermitte’s phenomenon. Our data underline the clinical 
importance of pain in multiple sclerosis and indicate that a 
more severe disease is associated with a higher risk of 
developing neuropathic pain. The prevalence of pain we 
found, lower than that reported in previous studies, may 
reflect the lower disease severity in our patients. 
Neurophysiological data show that whereas ongoing 
extremity pain is associated with spinothalamic pathway 
damage, Lhermitte’s phenomenon is related to damage of 
non-nociceptive pathways. These findings may be useful in 
designing a new therapeutic approach to neuropathic pain 
related to multiple sclerosis. 
 
The sixth chapter is dedicated to the mechanisms of pain in 
distal symmetric neuropathy. I and my colleagues 
performed a clinical, neurophysiological and 
histomorphological study on patients with neuropathic 
pain in distal symmetric neuropathy. In patients with 
distal symmetric polyneuropathy we assessed non-
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nociceptive Aβ- and nociceptive Aδ- and C-afferents to 
investigate their role in the development of neuropathic 
pain. We screened 2240 consecutive patients with sensory 
disturbances and collected 269 patients with distal 
symmetric polyneuropathy (57% with pain and 43% 
without). All patients underwent the Neuropathic Pain 
Symptom Inventory to rate ongoing, paroxysmal and 
provoked pains, a standard NCS to assess Aβ-fibre 
function, LEPs to assess Aδ-fibre function, and skin biopsy 
to assess the unmyelinated innervations of the 
epidermidis. Patients with pain had the same age, but a 
longer delay since symptom onset than those without . 
Loss of intraepidermal  innervation did not correlate with 
the  presence of neuropathic pain. Whereas the LEP 
amplitude was significantly lower in patients with pain  
than in those without , NCS  and intraepidermal fibre 
nerves data did not differ between groups. LEPs were 
more severely affected in patients with ongoing pain than 
in those with provoked pain. Our findings indicate that the 
impairment of Aβ-fibres has no role in the development of 
ongoing or provoked pain. In patients with ongoing pain 
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the severe LEP suppression and the correlation between 
pain intensity and LEP attenuation may indicate that this 
type of pain reflects damage to nociceptive axons. The 
partially preserved LEPs in patients with provoked pain 
suggest that thistype of pain is related to the abnormal 
activity arising from partially spared and sensitised 
nociceptive terminals. Because clinical and 
neurophysiological abnormalities followed similar patterns 
regardless of aetiology, pain should be classified and 
treated on mechanism-based grounds. 
 
In the seventh chapter I treated the mechanisms of 
allodynia in distal symmetric polyneuropathy allodynia. 
Patients with painful neuropathy frequently complain of 
allodynia, i.e. pain in response to a normally non-painful 
stimulus. Many authors consider allodynia to be generated 
by sensitization of the second-order nociceptive neurons to 
Aβ-fibre input (central sensitization). With the hypothesis 
that patients suffering from this type of pain probably have 
a relative sparing of Aβ-fibres in comparison with patients 
with ongoing pain only, we sought aimed at seeking 
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information on mechanisms underlying allodynia. In 200 
patients with distal symmetric polyneuropathy (114 with 
pain, 86 without) we assessed non-nociceptive Aβ- and 
nociceptive Aδ-afferents to investigate their role in the 
development of allodynia. After a detailed clinical 
examination and pain questionnaires patients underwent a 
standard nerve conduction study (NCS) to assess Aβ-fibre 
function, and LEPs to assess Aδ-fibre function. Forthy-four 
out of 114 patients with painful neuropathy suffered from 
allodynia. While NCS data did not differ between patients 
with and without allodynia,  LEP amplitude was higher in 
patients with allodynia than in those without. Our data 
argue against a role of Aβ-fibres and central sensitization 
as the main mechanism for the development of allodynia 
in distal symmetric polyneuropathy. The partially 
preserved LEPs in patients with allodynia suggests that 
this type of pain might be related to the abnormal 
reduction of mechanical threshold of nociceptive terminals 
(peripheral sensitization). 
 
13 
 
In the eighth chapter I treated neuropathic pain in patient 
with crioglobulinemia. The study aimed at gaining 
information on peripheral neuropathy and neuropathic 
pain in patients with cryoglobulinaemia. We collected 48 
consecutive patients with cryoglobulinaemia. All patients 
underwent a standard NCS to assess A-fibre function, 
LEPs to assess A-fibre function, and skin biopsy to assess 
C-fibre terminals. We used DN4 questionnaire to diagnose 
neuropathic pain, and the Neuropathic Pain Symptom 
Inventory to rate the intensity of the different qualities of 
neuropathic pain. Thirty patients had a peripheral 
neuropathy. Twenty-three had neuropathic pain as 
assessed by the DN4 questionnaire. NPSI questionnaire 
showed that the most frequent type of pain was the 
burning pain. Patients with peripheral neuropathy had an 
older age than those without .  The duration of the disease 
correlated with the density of epidermal innervation as 
assessed by skin biopsy. The severity of the ongoing 
burning pain correlated with the amplitude of LEPs, but 
not with the density of epidermal innervation . Our 
findings showed that an older age is associated with the 
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development of peripheral neuropathy, and a longer 
duration of disease with a more severe peripheral nerve 
damage, as assessed by skin biopsy. The correlation 
between the intensity of ongoing pain and LEP attenuation 
indicate that neuropathic pain reflects damage to 
nociceptive axons.  
 
In the ninth chapter I discussed the research on a peptide, 
the kiss-peptine, whose antagonist could be a new 
analgesic drug. More studies should be perform in the next 
future about it . Kisspeptin is a neuropeptide known for its 
role in the hypothalamic regulation of the reproductive 
axis. Following the recent description of kisspeptin and its 
7-TM receptor, GPR54, in the dorsal root ganglia and 
dorsal horns of the spinal cord, we examined the role of 
kisspeptin in the regulation of pain sensitivity in mice. 
Immunofluorescent staining in the mouse skin showed the 
presence of GPR54 receptors in PGP9.5-positive sensory 
fibers. Intraplantar injection of kisspeptin (1 or 3 nmol/5 
μl) induced a small nocifensive response in naive mice, and 
lowered thermal pain threshold in the hot plate test. Both 
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intraplantar and intrathecal (0.5 or 1 nmol/3 μl) injection of 
kisspeptin caused hyperalgesia in the first and second 
phases of the formalin test, whereas the GPR54 antagonist, 
p234 (0.1 or 1 nmol), caused a robust analgesia. 
Intraplantar injection of kisspeptin combined with 
formalin enhanced TRPV1 phosphorylation at Ser800 at the 
injection site, and increased ERK1/2 phosphorylation in 
the ipsilateral dorsal horn as compared to naive mice and 
mice treated with formalin alone. These data demonstrate 
for the first time that kisspeptin regulates pain sensitivity 
in rodents and suggest that peripheral GPR54 receptors 
could be targeted by novel drugs in the treatment of 
inflammatory pain.  
 
In the tenth last chapter I gathered all the conclusion of the 
single studies. Here I tried to associate each quality of pain 
to an underling pathophysiological alteration, since the 
aim of y studies was to show  the correlation between 
clinical manifestations of neuropathic pain and the  
underlying alteration of the different groups of fibers (A-β, 
A-δ or C). 
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Chapter 2: Neuropathic pain and methods to examine the 
somatosensory system 
_______________________________________ 
 
 
1. Introduction 
Injury to the nervous system causes loss of sensation in the 
territory innervated by the damaged nervous structure 
(nerve root, nerve fascicle, peripheral nerve, spinal 
segment, cortical structure, etc.). In a limited number of 
patients, such damage is followed by long-lasting, 
occasionally persistent, pain termed neuropathic pain (NP) 
in the damaged innervations territory. NP conditions 
consist of a series of different diseases and conditions 
ranging from nerve injury due to cancer over neuropathies 
following diabetes to diseases  and lesions of the central 
nervous system (CNS). In addition to al long list of 
different  aetiologies causing neropathic, these pains also 
differ in anatomical location and can localized anywhere 
from the peripheral nociceptor to the highest centres in the 
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brain. According to the International NP is defined as 
“Pain arising as a direct consequence of a lesion or disease 
affecting the somatosensory system” [1]. According  to this, 
NP is now proposed to be defined the consequences of 
injury to the nervous system include a series of 
neurobiological events resulting in sensitization of those 
parts of the nervous system that have been deprived of 
their normal patterned afferent input. While primarily 
described for diseases and lesions affecting the peripheral 
nervous system, NP may also be a feature of a certain 
central disorders. Although probably more complex in 
nature, central share some of the same phenomena seen in 
peripheral NP, i.e. sensory loss in part of the territory with 
pain, and the paradox presence of lost sensibility and 
hypersensitivity to one or several sensory submodalities 
[2]. It is clear that NP is not a single disease but represents 
a syndrome, i.e. a constellation of specific symptoms and 
signs with multiple potential underlying aetiologies. 
Hence, an accurate neurological history and neurological 
examination, including sensory testing, is most important 
to reach a diagnosis and to postulate the presence of a NP 
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syndrome. The elucidation of underlying disease aetiology 
and the dissection of pain will in practice often occur 
simultaneously. The following is a brief description of 
steps in assessing a NP syndrome. The history will indicate 
whether the character and distribution of the pain is in 
accord with neuropathic criteria, and whether a relevant 
lesion or disease in the nervous system is probably 
responsible for the pain.  The clinical examination will 
determine the presence of negative (loss of function) and 
positive (hyperalgesia and/or allodynia) sensory signs, for 
one or more sensory modalities affecting the 
somatosensory system, and their relevance to the 
underlying disease or lesion. Further diagnostic tests can 
be conducted to either document the presence of a specific 
underlying neurological or confirm a sensory lesion within 
the pain distribution. 
 
1.2 Clinical symptoms  and pathophysiological mechanisms 
The symptoms and signs in NP can be divided into 
negative and positive phenomena. The negative symptoms 
and signs reflect the damage to the CNS resulting in partial 
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or complete sensory loss and numbness in the distribution 
of the nervous structure that has been damaged. The 
positive phenomena such as allodynia, hyperalgesia, and 
hyperpathia are all manifestations of hyperexcitability in 
the nervous system. Clinically, central  NP is characterized 
by the presence of spontaneous ongoing pain and various 
types of evoked pains often occurring in different 
combinations.  The examination of a patient complaining 
of pain aims at clarifying the underlying disease and 
understanding whether the pain is nociceptive, 
neuropathic, psychogenic, or a combination of the three 
types. Before suspecting neuropathic pain, the physician 
must exclude nociceptive pain . The diagnostic procedure 
is based on a meticulous medical history and systematic 
clinical examination. Laboratory tests and radiological 
examinations may be indicated to confirm or exclude the 
suspected disease.  The patient’s history should be 
searched to identify a possible association of  the onset of 
pain with current diseases, trauma and surgery.  Patients 
in whom NP is suspected must first undergo sensory 
examination. Tactile sense is best assessed with a piece of 
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cotton wool, pinprick sense with a wooden cocktail-stick, 
thermal sense with warm and cold objects (e.g. metal 
thermorollers), and vibration sense with a 128-Hz tuning 
fork.  The sensory examination should search for negative 
(i.e., sensory loss) and positive (i.e., hyperalgesia and 
allodynia) sensory findings. The distributions of these 
sensory abnormalities should be neuroanatomically logical, 
namely, compatible with a definite lesion site. Despite 
being the basis of the assessment, clinical examination is 
not always sensitive enough to detect an underlying 
disease. Hence clinical, neurophysiological and 
radiological evaluations are complementary. 
Ongoing pain. These pains are spontaneous and may be 
continuous  or paroxysmal. The character of these pains 
differs, but it can be shooting, shock-like, aching, 
cramping, crushing, smarting, etc. Episodic, paroxysmal 
types of pain are second-lasting shooting, electric, shock-
like, or stabbing in their character. 
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Evoked pains. The stimulus-evoked pains are classified 
according to the type of stimulus that provokes them, such 
as mechanical, thermal, or chemical stimuli.  
In some patients, all these symptoms may be present; in 
others only one type of hypersensitivity is present. So a 
series of stimuli need to be applied to document or exclude 
abnormality. Evoked pains are usually brief, lasting only 
for the duration of the stimulation, but sometimes they can 
persist even after cessation of the stimulation causing after-
sensations, which can last for minutes, hours, and even 
days. In such cases, the distinction between evoked and 
spontaneous types of pain can be difficult. Patients 
suffering from NP often complain of sensory deficits and 
different types of pain combined in various ways, such as 
electrical shock like sensations, or provoked by various 
stimuli, e.g. gentle brushing or cold water. The complex 
sensory profile of NP reflects the various 
pathophysiological mechanisms underlying. Although in 
some etiologic categories of NP specific  types of pain may 
predominate, none of them are etiologic specific. Hence 
patients suffering from an  identical disease may present 
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with heterogeneous sensory signs and symptoms. The 
diagnostic workup should therefore aim to detect specific 
sensory profiles through clinical examination, 
questionnaires dedicated to NP, and laboratory tools. 
Defining precise sensory profiles is crucial to successful NP 
management because they probably arise through different 
underlying mechanisms and thus probably respond 
differently to treatment [3,4]. Clinical examination and 
pain questionnaires dedicated NP can reliably distinguish 
precise sensory profiles in patients with NP whatever the 
cause. Current research findings indicate that whereas  
provoked pains probably arise through multiple 
mechanisms., the mechanisms responsible for spontaneous 
pains show no etiologic specific differences. Conversely, 
recent neurophysiological studies suggest that 
spontaneous paroxysmal pain reflects demyelination of 
non nociceptive, large myelinated fibers [5,6]. That specific 
sensory profiles can be distinguished across different 
neuropathic pain conditions, might be the starting point 
for a mechanism based classification of NP. 
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1 The functional and morphological assessment of the 
somatosensory system 
1.1  Clinical examination and screening tools 
History and clinical examination are a requirement to 
confirm the presence of a NP syndrome, and also an 
important step in reaching an aetiological diagnosis for 
NP. Several tools essentially based on pain descriptors 
have been proposed for the purpose of distinguishing NP 
from non-NP  or characterizing multiple neuropathic 
phenotypes. The Douleur Neuropathique en 4 questions 
(DN4) contains seven items related to symptoms and three 
related to clinical examination   [7]. A total score =4 out of 
10 suggests NP. The DN4 showed 83% sensitivity and 90% 
specificity when compared to clinical  diagnosis in the 
development study. The seven sensory descriptors can be 
used as a self-report questionnaire with similar results. The 
tool was developed and validated in French and translated 
into 15 languages. The DN4 has been used in 
epidemiological studies in general population and 
diabetics. The Neuropathic Pain Symptom Inventory 
(NPSI), the pain quality assessment tool devoted to NP 
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assessment, was originally validated in French and has 
been submitted to linguistic validation in 50 other 
languages. One study found that several NP dimensions of 
the NPSI were particularly sensitive to treatment effect. 
The structure of the NPSI makes it factorial suitable to 
capture different aspects of NP with presumably distinct 
mechanisms. The main advantage of screening tools is to 
identify potential patients with NP, particularly by non-
specialists. However, these tools fail to identify 10–20% of 
patients with clinician diagnosed NP, showing that they 
cannot replace careful clinical judgment. Pain quality 
assessment measures are useful to discriminate amongst 
various pain mechanisms associated with distinct 
dimensions of NP experience . The NPSI is recommended 
to evaluate treatment effects on neuropathic symptoms or 
their combination , but should also be used in future trials 
to try to predict treatment outcome and better define 
responder profiles.  
Quantitative sensory testing is a psychophysiological 
measure of perception in response to external stimuli of 
controlled intensity. Detection and pain thresholds are 
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determined by applying stimuli to the skin in an ascending 
and descending order of magnitude. Mechanical sensitivity 
for tactile stimuli is measured using von Frey hairs or 
Semmes-Weinstein monofilaments, pinprick sensation 
with weighted needles and vibration sensitivity with a 
tuning fork or an electronic vibrameter; thermal perception 
and thermal pain are measured using a probe that operates 
on the Peltier principle . Most QST studies are still 
dedicated to the assessment of sensory small fibre function 
only, assuming that large fibre function was probably 
documented by standard clinical neurophysiology. This 
bias precludes any analysis on the relative importance of 
small vs. large sensory fibre function deficits in NP 
syndromes.QST is used for diagnosis and follow-up of 
small fibre neuropathy  [8,9], and its usefulness is agreed in 
the early diagnosis of diabetic neuropathy. Quantitative 
sensory testing is particularly appropriate to quantify 
positive sensory phenomena, like mechanical and thermal 
allodynia and hyperalgesia, which may help characterize 
painful neuropathic syndromes, and predict or monitor 
treatment effects. In particular, pharmacological and non-
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pharmacological treatment trials using QST found effects 
on dynamic mechanical allodynia, pinprick hyperalgesia 
and sensory loss, whereas treatment efficacy was predicted 
by thermal detection thresholds, vibration detection 
thresholds, heat hyperalgesia and dynamic mechanical 
allodynia [10,11]. Quantitative sensory testing can be used 
in the clinic along with bedside testing to document the 
sensory profile. Because abnormalities have often been 
reported in non-NPs as well, QST cannot be considered 
sufficient to separate differential diagnoses . QST is helpful 
to quantify the effects of treatments on allodynia and 
hyperalgesia and may reveal a differential efficacy of 
treatments on different pain components. Neurological 
examination in suspected NP should include assessment o 
motor, sensory, and autonomic phenomena in order to 
identify all signs of neurological dysfunction. Tactile sense 
is best assessed with a piece of cotton wool, pinprick sense 
with wooden cocktail stick, thermal sense with warm and 
cold objects (e.g., metal thermorollers) and vibration sense 
with a 128-Hz tuning fork (Table 1). To evaluate 
mechanical allodynia- hyperalgesia, we recommend the 
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use of simple tools such as a brush and at least one high-
intensity weighted pinprick or von Frey filament (e.g. 128 
mN). The evaluation of pain in response to thermal stimuli 
is best performed using the computerized thermotest, but 
we do not recommend the systematic measure of thermal 
stimuli except for pathophysiological research or treatment 
trials. A simple and sensitive tool to quantify pain induced 
by thermal stimuli in clinical practice is still lacking.  
 
 
    Table 1. Summary of choice methods of assessing nerve. 
function per    sensation 
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 Neurophysiological tests: elettroneurography, 
somatosensory-evoked potentials and laser-evoked 
potentials 
 
Nerve conduction studies  (NCS) allows to investigate Aβ-
fibres. Patient with suspected distal symmetric neuropathy 
usually underwent motor and sensory NCS using surface 
recording electrodes with standard placement. Amplitudes 
nerve action potentials  of ulnar , median  and sural 
sensory and conduction velocities are examined. 
Compound motor action potential amplitude and 
conduction velocity of peroneal, tibial, ulnar and median 
nerves are usually also examined. When appropriate , F-
wave examination f the same nerves is carried out by 
delivering 20 random stimuli . Somatosensosory evoked 
potential (SEP)  is obtained through the direct activation of 
a peripheral nerve fibre or its receptor, the relayed 
peripherally and centrally up to the primary 
somatosensory cortex. Most frequently, to elicit SEPs 
electrical stimuli are applied transcutaneously over a 
sensory or mixed sensory/motor nerve (e.g. nervus 
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medianus for upper limbs and nervus tibialis posterior for 
lower limbs). Electrical stimuli activate fast-conducting 
myelinated large nerve fibers (Aβ) with low electrical 
activation thresholds. The scalp activity related to the 
electrical stimulation of peripheral nerve fibers can be 
separated into short-, middle-, and late-latency brain 
responses. Pathological SEPs indicate the presence or 
damage along large size non-nociceptive afferents or the 
sensor nervous system. This technique is useful to 
determine the origin o a nerve lesion or to complete the 
exploration on the nervous system, but not to assess 
nociceptive pathway’s function [12].   Current 
neurophysiological assessment of the trigeminal system 
comprises recordings of trigeminal reflex responses. The 
blink reflex assesses the ophthalmic division and consists 
of an early response, ipsilateral to the side of the 
stimulation (R1) and a late, bilateral, response (R2); the 
reflex responses are recorded after mechanical or electrical 
stimulation of the supraorbital region. The masseter 
inhibitory reflex studies the second an third trigeminal 
division; the early, SP1, and late , SP2, components are 
30 
 
elicited after mechanical or electrical stimulation of the 
maxillary  or mandibular division. Trigeminal reflexes 
assess the  function of  large myelinated A-β afferents from 
all the trigeminal territories, aswell as their trigeminal 
central circuits in the midbrain, pons and medulla. 
Large -size, non-nociceptive afferents (i.e., those that do 
not carry pain) have a lower electrical threshold than 
small-size, nociceptive afferents. Unless special techniques 
are used, i.e., experimental blocks or stimulation of special 
organs (cornea, tooth pulp, glans), electrical stimuli 
unavoidably also excite large afferents, thus hindering 
nociceptive signals. Hence standard neurophysiological 
responses to electrical stimuli, such as NCS and SEPs, can 
identify, locate, and quantify damage along the peripheral 
or central sensory pathways, but they do not assess 
nociceptive pathway function. For many years researchers 
have tried numerous techniques for selectively activating 
pain afferents. The currently preferred approach uses laser 
stimulators to deliver radiant-heat pulses that selectively 
excite the free nerve endings (Aδ and C) in the superficial 
skin layers. Consensus from over 200 studies now confirms 
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that late laser-evoked potentials (A-δ LEPs) are nociceptive 
responses. Late LEPs are the easiest and most reliable 
neurophysiological tools for assessing nociceptive pathway 
function and are diagnostically useful in peripheral and 
central neuropathic pain [13]. In clinical practice, their 
main limitation is that they are currently available in too 
few centres . Ultralate LEPs (related to C-fibre activation) 
are technically more difficult to record, and few studies 
have assessed their usefulness in patients with neuropathic 
pain. They are usually recorded after  laser stimuli (biggers 
diameter and longer duration than Aδ stimuli setting) 
applied in trigeminal regions, where the density of full C 
fiber is higher and the  distancy  from the central nervous 
system is lower than any other region in the body . The 
radiant-heat pulse stimuli delivered by laser stimulators 
are absorpted by free nerve endings for Aδ- and C-fibers 
located within  superficial skin layer. Aδ- and C-fibers 
possess different thermal  activation thresholds. Thus , in 
function of the quantity of thermal energy that is delivered  
to the skin, it is possible to record brain responses that are 
either linked to Aδ nociceptor activation (late LEPs) or to 
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C-fiber nociceptors activation (ultralate LEPs). In scalp 
recordings, the early lateralized potential culminating at 
150–180 ms over the temporal regions and inverting phase 
at the midline (N1/P1) would be dominated by opercular 
(and perhaps SI) activity, while the large vertex negative-
positive response appears as the resultant of late insular 
and anterior cingulate activity [15]. Pain conditions that 
may benefit from an assessment with LEPs are 
neuropathies, radiculopathy, syringomyelia, multiple 
sclerosis and cerebral infarctions including Wallenberg’s 
syndrome. Apart from allowing to discern Aβ from Aδ and 
or C fiber lesions, LEP can explore skin territories that are 
outside conventional sensory nerve territories (examined 
with NCS or SEPs) such as the face (trigeminal neuralgia) 
or the thoracic region (post-herpetic neuralgia); each 
dermatome that is not too hairy is accessible with the laser 
stimulus. 
 
1.2  Skin biopsy and intraepidermal fibers quantification 
Punch skin biopsy can quantify unmyelinated nerve fibres 
by measuring the density of intra-epidermal nerve fibres 
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(IENF). IENF loss has been shown in various neuropathies 
characterized by small-fibre axonal loss. Punch skin biopsy 
is easy to do, minimally invasive, and optimal for follow-
up. Despite these advantages, it is useless in central pain 
and demyelinating neuropathy, and is currently available 
only in few research centres [15]. 
 Skin biopsy is most commonly performed using a 3-mm 
disposable punch under sterile technique, after topical 
anesthesia with lidocaine. No suture is required (Fig. 1). A 
shallow biopsy (3-4 mm) is adequate to study epidermal 
nerve fibers, whereas a deeper biopsy (6-8 mm) is required 
to include sweat glands, hair follicles, and artero-venous 
anastomosis. 
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Fig. 1     Skin biopsy is most commonly performed using a 3-
mm disposable punch under sterile technique, after topical 
anesthesia with lidocaine. No suture is required. 
 
To optimize the sampling of such structures and 
myelinated fibers in hairy skin, particular attention should 
be paid to include a hair in the specimen [16] . The current 
technique was developed at the Karolinska Institute [17], 
and later standardizewd at the University of Minnesota 
[18] and at the Johns Hopkins University [19]. A less 
invasive sampling method  is the removal of the epidermis 
alone by applying a suction capsule to the skin. With this 
35 
 
method, there is no bleeding, and local anesthesia is not 
needed. However, the method does not provide 
information on dermal and sweat gland nerve fibers. 
Moreover, thus far it has not been systematically used to 
investigate patients with small fiber neuropathy. This 
technique was developed at the University of Minnesota 
[20]. In most studies, hairy skin biopsies were obtained 
from the distal part of the leg (10 cm above the lateral 
malleolus), in some from the calf and the paraspinal 
region, and in many of them also from the upper lateral 
aspect of the thigh (20 cm below the anterior iliac spine) or 
other proximal locations where chosen to detect the length-
dependent loss of nerve fibers, which is typical of axonal 
polyneuropathy. These sites may also be sampled in the 
case of a non-length-dependent ganglionopathy. When 
skin biopsy is taken from other body sites for evaluation of 
a unilateral process, a control biopsy from similar non-
affected region should be taken.  
After skin biopsy is performed, the specimen is 
immediately  fixed in cold fixative for approximately 24 h 
at 4°C, then kept in a cryoprotective solution for one night, 
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and serially cut with freezing microtome or a crystat. The 
first and last few sections should not be used for nerve 
examination because of possible artefacts. Most studies for 
bright-field microscopy used 2% paraformaldehyde-lysine 
periodate  (2% PLP), whereas most studies for indirect 
immunofluorescence with or without confocal microscopy 
used Zamboni’s (2% paraformaldehde, picric acid) fixative. 
Either bright-fild immunohistochemistry ot 
immunofluorescence with or without confocal microscopy 
has been used, but the technique does not affect the 
reliability of skin biopsy in assessing intraepidermal nerve 
fiber (IENF) loss in neuropathy. However, no studies has 
been designed yet to compare the two techniques. 
Quantification of IENF density using bright-field 
immunohistochemistry was mostly based on the 
assessment of the number of fibers per linear 
measurement. Significant correlation with a stereologic 
technique supported the reliability of linear IENF density 
[21].  IENF are counted either under the light microscope at 
high magnification (i.e 40X objective) or using software for 
image analysis. The length of the epidermal surface is 
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measured using software for biological measures. The 
density is calculated in at least three sections as the number 
of IENF per length of the section (IENF/mm)(Fig.2). Other 
studies reported the IENF density per skin surface area 
[22]. Quantification of  IENF density using confocal 
immunofluorescence technique is usually performed on 
images based on the stack of consecutive 2 µm optical 
sections (usually 16 sections) for a standard linear length of 
epidermis. The thickness of skin sections varies from 32 to 
60 µm. Four epidermal areas are selected for confocal 
images acquisition, two images on each of two different 
sections excluding areas containing hair follicles and sweat 
ducts. For quantitative analysis, IENF are counted at high 
magnification (i.e 40X objective) (Figure 3) for light 
microscope or (20X) for epifluorescence microscope (Figure 
4 and 5) or using a software for image analysis (e.g. 
Neurolucida, Microbrightfield) on digitized confocal 
images.  In both bright-field and immunofluorescence 
methods, single IENF crossing the dermal-epidermal 
junction are counted, whereas secondary branching is 
excluded from  quantification. No study provided 
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information or the rules for cunting IENF fragments, which 
have been comprehensively reviewed by Kennedy et al 
[23]. Intra- and interobserver variability, and 
interlaboratory agreement on IENF counts has been 
assessed [24]. 
The skin blister is an alternative technique to assess the 
epidermal innervations density. IENF density in blister 
roofs from foot and calf correlated with IENF density in 
skin biopsied from adjacent areas in 25 healthy subjects 
showing no systematic differences between skin biopsies 
and  blisters (P=0.29) or between pairs of blisters from the 
same location (P=0.15) [22]. No side effects have been 
reported in published studies, but no study focused on 
safety was performed. The density of IENF at the distal leg 
ranged from 13.8 ± 6.7/mm (mean ± SD) to 9.8 ± 3.6/mm ( 
mean ± SD).  
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Fig. 2 Light microscope immunostainting (x5) skin biopsy 50 
μm vertical sections   from the proximal (on the left) and distal 
(on the right) areas of the leg, The derma- epidermal junction 
is evident:  dark brown line, undulating in the thigh, more 
linear in the ankle.  Only nerve fibers crossing the junction are 
counted for the IENF density. Bar =60µm. 
 
 
Fig. 3 Light microscope immunostainting (X40) skin biopsy 
tissue from the right (A) and left (B) side of the second trigeminal 
division in a patient with emifacial atrophy.  Epidermal nerve 
fiber density measurements illustrated in 50 μm vertical sections, 
immunostained with the panaxonal marker anti-protein gene 
product 9.5 to demonstrate normal, fine, vertically arrayed 
unmyelinated nerve fibers within epidermis (arrows). And 
dermal nerve bundles (arrowheads) Bar =60µm. 
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Fg. 4 Epifluorescence microscope (x20) (using a software for 
image analysis- Neurolucida, Microbrightfield- on digitized 
confocal images) skin biopsy tissue from tigh of a voluntary.  In 
the 20 μm vertical sections, immunostained with the panaxonal 
marker anti-protein gene product 9.5 to demonstrate normal, 
fine, green vertically unmyelinated nerve fibers within  derma 
and epidermis.Vessels and basement membrane are in red 
(immunostained with the markers anti-collagen IV), nuclei are in 
blu. Yellow bar =80µm. 
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A    
B   
Fg. 5 Epifluorescence microscope (x40) (using a software for image 
analysis- Neurolucida, Microbrightfield- on digitized confocal images) 
skin biopsy tissue from the first trigeminal division in a normal subject 
(A) and in a patient with postherpetic neuroalgia: it is evident the severe 
loss of nerve fibers (green coloured after immunostained with PG 9.5) in 
figure B.  In the 20 μm vertical sections, immunostained also with anti-
collagene IV to demonstrate the epidermal basic membrane (red 
coloured) where the nerve fibres get fre of myelin; this marker also 
coloured basic membrane of lood vessels in the derma. White bar  
=60µm. 
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The largest normative study [25] included 188 healthy 
subjectsfrom three different laboratories (Maastricht, 
Ferrara, Milan) and stratified the study population per age 
and gender, providing normative values per decade. 
The authors reported that IENF density at the distal leg is 
lower in men than in women, that weight and height do 
not have any significant impact, and that values  decline 
with age (Table 2). Norrnative reference values are 
available for bright-field imunohistochemistry but not yet 
for confocal immnofluorescence or blister technique.   The 
most common side effect was a mild infection because of 
improver wound management recovering with topical 
antibiotic therapy. The only other complication reported 
was excessive bleeding which did not need suture.  
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Table 2. Intraepidermal nerve fiber (IENF) density normative 
values  for clinical use (reproduced from Bakkers et al., 
Neurology) 
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2.4 Functional neuroimaging 
Functional neuroimaging Positron emission tomography 
(PET) and functional magnetic resonance imaging (fMRI) 
measure with different methods cerebral blood flow (rCBF) 
or metabolic activity in defined brain regions. Activation 
studies investigate local synaptic changes specifically 
associated with a given task or a particular stimulus by 
comparing statistically activated and control conditions. 
Functional neuroimaging has disclosed a network of brain 
regions jointly activated by noxious stimuli (labeled -pain 
matrix). Activation of the lateral thalamus, SI-SII and 
posterior insula are thought to be related to the sensory-
discriminative aspects of pain processing, whilst mid-
anterior cingulate, posterior parietal and prefrontal cortices 
participate in the affective and attentional concomitants of 
pain sensation [26]. In unilateral spontaneous neuropathic 
pain, moderate but converging evidence from independent 
groups indicates  decreased resting rCBF in contralateral 
thalamus, and reversal of this abnormality by analgesic 
procedures (but only case reports or small series with <20 
patients [27]). Should this be confirmed in larger series, 
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thalamic hypoperfusion might be used in the future as a 
marker of NP and restoration of thalamic blood flow for 
treatment monitoring. In patients with provoked 
neuropathic pain, allodynia and hyperalgesia have been 
associated with amplification of the thalamic, insular,  SI, 
SII and prefrontal–orbitofrontal responses, but not 
anterior–perigenual cingulate [28]. Neuropathic allodynia 
has been shown to enhance insular activity ipsilateral to 
pain [29] suggesting that a shift in hemispheric balance 
might contribute to the allodynic experience. Again, the 
total number of reported patients (n = 80) is still too small 
to support any diagnostic application; however, 
neuropathic allodynia has shown a different activation 
pattern than nonneuropathic allodynia  which may open 
diagnostic perspectives.  
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Chapter 3: Pathophysiology of pain in postherpetic 
neuralgia: A clinical and neurophysiological study 
 
Chapter based on: Pathophysiology of pain in postherpetic neuralgia: A 
clinical and neurophysiological study . A. Truini, F. Galeotti, M. 
Häänpää, R. Zucchi, A. Albanesi, A. Biasiotta,A. Gatti, G. Cruccu. 
Pain 2008.140: 405–410 
 
1. Introduction 
Postherpetic neuralgia (PHN) is an exceptionally drug-
resistant neuropathic pain that persists after a herpes 
zoster rash has healed [31]. In PHN, the Abnormal sensory 
function may manifest as hypoesthesia, involving all 
sensory modalities, and pain. Most patients with PHN 
describe three types of pain: a constant deep, aching or 
burning pain, a paroxysmal, lancinating pain, and 
allodynia (i.e. pain provoked by normally non painful 
stimulus). Two-thirds of the patients report mechanical 
allodynia, and some patients have cold allodynia. Some 
patients also complain of itching that may be even more 
annoying than the pain itself [22,23]. PHN related pain 
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results from changes in peripheral and central nervous 
system somatosensory processing [9]. Although PHN most 
commonly involves the thoracic dermatomes, in 23% of 
patients it affects the ophthalmic division of the trigeminal 
nerve [32]. Current neurophysiological assessment of the 
trigeminal system comprises recordings of trigeminal 
reflex responses [6] and laser evoked potentials [11]. The 
blink reflex assesses the ophthalmic division and consists 
of an early response, ipsilateral to the side of the 
stimulation (R1) and a late, bilateral, response (R2), both 
mediated by large myelinated, A-β fibers [3]. Because the 
blink reflex is mediated by non-nociceptive A-β fibers, it 
provides no information on trigeminal nociceptive 
pathway function [3]. The best tool for assessing trigeminal 
nociceptive pathway function is laser stimulation [27]. 
Laser generated radiant heat pulses selectively excite free 
nerve endings in the superficial skin layers, activate 
myelinated A-δ and unmyelinated C-fibers [28], and evoke 
scalp potentials generated by the opercular-insular cortex 
and cingulate gyrus [12]. Although skin biopsy studies 
have shown a severe loss of epidermal-free nerve endings 
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in the affected dermatomes, such studies used exclusively 
a pan-neuronal marker (PGP 9.5), which does not allow 
differentiating the nerve endings of myelinated (Aδ) from 
those of unmyelinated (C) neurons [21]. Previous 
neurophysiological studies investigated the A-β fiber-
mediated blink reflex [20] and A-δ LEPs [29] in patients 
with PHN. No studies have systematically assessed 
neurophysiological responses related to non-nociceptive 
and nociceptive fibers in patients with PHN, or tried to 
correlate neurophysiological abnormalities reflecting 
specific fiber damage with PHN pain; this information 
might be useful for a better understanding of pain 
mechanisms. To seek information on trigeminal nerve 
function and pain mechanism in ophthalmic PHN, we 
assessed myelinated and unmyelinated fiber function by 
recording the blink reflex to measure A-beta fiber function, 
and LEPs to measure A-delta and C-fiber function, in 
patients with ophthalmic PHN. We then determined the 
diagnostic accuracy of the neurophysiological testing and 
the correlation of neurophysiological data, clinical sensory 
deficits, and pain. 
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2. Methods 
2.1. Patients 
We did a prospective, cohort study, recruiting consecutive  
patients with ophthalmic PHN from January 2006  to 
March 2008. The reference standard for the diagnosis of 
trigeminal PHN was the IHS diagnostic criteria: pain in the 
distribution of the ophthalmic division of the trigeminal 
nerve, herpetic eruption in the same territory, pain that 
precedes herpetic eruption by less than 7 days, and pain 
that persists after 3 months [16]. Exclusion criteria were 
neurological or dermatological disease other than PHN, 
cognitive impairment, diabetes, and herpes zoster-related 
corneal damage. Forty-one patients with ophthalmic PHN 
aged 50–88 years (mean 72.7; 19 F, 22 M) fulfilled inclusion 
criteria. Patients had a disease duration of 3–30 months 
(median: 5 months). All patients were receiving drugs for 
neuropathic pain. All patients gave their informed consent 
to undergo the procedure and the research was approved 
by the local Ethical Committee. 
 
 
55 
 
2.2. Clinical examination 
All patients underwent a general and neurological 
examination. Sensory disturbances were carefully assessed. 
Patients were examined for negative (tactile, pinprick, and 
thermal hypoesthesia) and positive symptoms (constant 
pain, paroxysmal pain, itching, mechanical and cold 
allodynia, and pinprick hyperalgesia). Patients were 
instructed to rate positive and negative sensory 
disturbances on an 11-point numerical rating scale ranging 
from 0 (no disturbance) to 10 (worst possible disturbance). 
The presence and the severity of negative symptoms were 
assessed by comparing the affected side with the mirror 
image of the normal side. Although we used a 
preformatted questionnaire all the questions and the 
clinical tests were always performed randomly. To avoid 
missing data we checked at the end of the whole 
examination if all items were fulfilled. 
 
2.3. Neurophysiological examination 
All patients underwent blink reflex recordings. Evaluation 
methods adhered to those indicated by the International 
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Federation of Clinical Neurophysiology (IFCN) [7]. The 
blink reflex was evoked by electrical stimulation (0.1 ms, 
25–45 mA) of the supraorbital nerve through surface 
electrodes. EMG signals were recorded from the orbicularis 
oculi through surface electrodes. We measured the latency 
of R1 of each side. To study LEPs we used a previously 
reported technique [5]. In brief, we used a 
neodymium:yttrium-aluminium- perovskite laser 
(Nd:YAP) (wavelength 1.34 mm, pulse duration 2–20 ms, 
maximum energy 7 J) with fiber-optic guidance. Laser 
pulses of relatively high intensity (119–178 mJ/mm2), short 
duration (5 ms), and small diameter (5 mm), elicited 
pinprick sensations related to Aδ fiber input. Laser pulses 
of lower intensity (38–76 mJ/mm2), relatively long 
duration (10 ms) and large diameter (10 mm), elicited 
purely warmth sensations related to C-fiber input. Laser 
pulses were directed to the supraorbital skin. The laser 
beam was shifted slightly after each stimulus. The 
interstimulus interval was varied pseudorandomly (10–15 
s). Subjects lay on a couch and wore protective goggles. 
They were instructed to keep their eyes open and gaze 
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slightly downwards. To determine the laser perceptive 
threshold we delivered a series of stimuli at increasing and 
decreasing intensity, and defined the perceptive threshold 
as the lowest intensity at which the subjects perceived at 
least 50% of the stimuli. The main  LEP complex, N2–P2, 
was recorded through disk electrodes from the vertex (Cz) 
referenced to the nose. From 10 to 20 trials devoid of 
artifacts were collected and averaged off line. We 
measured peak latency and amplitude (peak-to-peak) of 
the main N2–P2 vertex complex. We do not report data 
About the earlier, negative (N1) component, because in our 
laboratory, in patients, it is less reproducible than the N2–
P2 vertex complex, and thus it is not routinely recorded for 
clinical purposes. For both blink reflex and LEPs to 
distinguish Abnormal from normal data we used the 
unaffected side as a control. The blink reflex responses 
were considered Abnormal when the R1 latency exceeded 
1.2 ms the latency of the normal side or was Absent [7]. 
LEPs were considered Abnormal when Absent [29]. All 
neurophysiological recordings were performed by 
technical staff and stored on disk or printed. Two authors, 
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blind to the side of disease, measured the responses and 
assessed abnormalities. 
 
3. Statistics 
We used the Kolmogorov–Smirnov test to assess the 
normal distribution. Paired t-test was used to analyze the 
between-side differences of normally distributed data such 
as the latency of the R1 blink reflex, A-δ LEP, and C-LEP, 
and the laser perceptive thresholds. The Wilcoxon 
matched-pair test was used for amplitude of Ad and C-
LEPs, which did not show a normal distribution. The 
diagnostic accuracy of neurophysiological testing was 
evaluated with Fisher’s exact test, with the calculation of 
sensitivity and specificity and their 95% confidence 
intervals (CI). We studied the correlations between the 
side-to-side difference of neurophysiological responses and 
sensory disturbances (tactile, pinprick, and thermal 
hypoesthesia, itching, constant and paroxysmal pain, and 
mechanical allodynia) with the nonparametric Spearman’s 
R correlation coefficient. P < 0.01 was considered 
significant. All results are reported as means ± SD. 
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4. Results 
4.1. Clinical findings 
Most patients reported sensory deficits involving all 
sensory modalities simultaneously. Of the 41 patients 
studied, 29 reported tactile hypoesthesia (mean rating 4.4 ± 
1.6), 30 pinprick hypoesthesia (mean rating 4.6 ± 1.7), and 
24 thermal hypoesthesia (mean rating 4.8 ± 1.7). Among 
sensory symptoms, 24 patients reported paresthesias 
(mean rating 5.6 ± 1.5), and 26 itching (mean rating 5.8 ± 
2.4). Whereas most patients (29 of 41 patients) complained 
of constant pain, 18 patients had mechanical dynamic 
allodynia, 16 patients paroxysmal pain, 9 patients 
hyperalgesia and 8 patients cold allodynia (mean ratings, 
for constant pain  5.4 ± 1.8, mechanical dynamic allodynia 
5.5 ± 1.6, paroxysmal pain 6.2 ± 1.9, hyperalgesia 5.2 ± 1.2, 
and cold allodynia 4.1 ± 1.2). 4.2. Neurophysiological 
findings Of the 41 patients who underwent blink reflex 
testing, R1 blink reflex was Absent in 17 and delayed in 16 
patients. In the 24 patients with normal or delayed 
responses, the latency of the R1 blink reflex was far longer 
after stimulation of the affected side than after stimulation 
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of the normal side (P < 0.001, paired t-test) (Fig. 1). The 
laser perceptive threshold related to A-δ fibers was 
significantly higher after stimulation of the affected side 
than after stimulation of the normal side (P < 0.001). The 
mean A-δ LEP latency after stimulation of the affected side 
was not significantly delayed (P > 0.20). The A-δ LEP 
amplitude was lower after stimulation of the affected side 
than after stimulation of the normal side (P < 0.001, 
Wilcoxon test) (Fig. 1). Of the 41 patients tested, 22 patients 
had Absent responses on the affected side, and four of 
them also on the normal side. The laser perceptive 
threshold related to C-fibers was significantly higher after 
stimulation of the affected side than after stimulation of the 
normal side (P < 0.001, paired t-test). The mean C-LEP 
latency after stimulation of the affected and normal side 
was similar (P > 0.2). The C-LEP amplitude was lower after 
stimulation of the affected side than after stimulation of the 
normal side (P < 0.001, Wilcoxon test). In 27 of the 41 
patients, laser stimulation of the affected side failed to 
evoke reproducible brain potentials (Fig. 1). In 12 of these 
patients, C-LEPs were not reproducible or markedly 
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dampened also after stimulation of the normal side. 
Abnormal neurophysiological responses were strongly 
associated with affected side (P < 0.0001; Fisher’s exact 
test). All but three patients had at least one Abnormal 
response on the affected side; the sensitivity was 93% (CI: 
80–98). Twelve patients had abnormal responses on the 
controlateral side, thus yielding a specificity of 71% (CI: 
55–84). Positive and negative predictive values were 0.76 
and 0.91. 4.3. Correlations The side difference in amplitude 
of both A-delta and C-LEPs correlated with the intensity of 
constant pain (P < 0.01, Spearman’s R correlation 
coefficient) (Fig. 2A and B). The side difference in R1 
latency correlated with the intensity of paroxysmal pain (P 
< 0.001) (Fig. 2C). The side difference in C-fiber perceptive 
threshold correlated with the magnitude of thermal 
hypoesthesia (P < 0.001). 
The correlation between the side difference in C-fiber 
perceptive threshold and intensity of itching only 
approached the statistical significance (P = 0.02). We also 
analyzed the following correlations, which did not reach 
statistical significance: the side difference in R1 latency 
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with magnitude of tactile hypoesthesia (P > 0.03), the side 
difference in perceptive threshold and amplitude of A-δ 
LEPs with magnitude of pinprick hypoesthesia (P > 0.03), 
the side difference in amplitude of C-LEPs with magnitude 
of thermal hypoesthesia and intensity of itching (P > 0.05); 
the intensity of mechanical allodynia with any of the three 
neurophysiological responses (P > 0.05); magnitude of 
sensory deficits and intensity of pain (P > 0.1). 
 
 
 
Fig. 1. Neurophysiological assessment.. 
Upper panel: this representative patient had 
constant pain as the predominant type of 
pain as assessed by the numerical rating 
scale. On the affected side R1 is minimally 
delayed whereas LEPs are absent. Lower 
panel: this representative patient had 
paroxysmal pain. On the affected side R1 is 
significantly delayed, A-delta LEP is 
Absent, C-LEP has a slight amplitude 
reduction. (A) Blink reflex, (B) A-delta LEP, 
(C) C-LEP. Horizontal calibration: 10 ms for 
(A), 200 ms for (B and C). Vertical 
calibration: 200 µV for (A), 20 µV for (B and 
C). 
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Fig. 2. Correlations between   
neurophysiological abnormalities and  
pain. (A and B) The intensity of constant pain, as 
assessed by the numerical rating scale (NRS), 
correlated with the side-to-side difference in A-delta 
LEP (P < 0.01, R = 0.4166) and C-LEP amplitude (P < 
0.01, R = 0.5762). (C) The intensity of paroxysmal 
pain had a correlation with the side-to-side 
difference in R1 latency (P < 0.001, R = 0.6404). 
Dashed lines indicate 95% confidence intervals from 
the mean 
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5. Discussion 
Our neurophysiological and clinical study assessed 
function of the three sets of cutaneous afferents (Aβ, Aδ, 
and C) in PHN. We found strong  correlations between the 
neurophysiological Abnormalities reflecting specific fiber 
damage and the various types of pain.  
 
5.1. Trigeminal nerve function in PHN 
Most patients had severe tactile, pinprick, and warmth 
hypoesthesia. Consistently, we found that all  the three 
neurophysiological responses (the R1 blink reflex, A-δ LEP, 
and C-LEP) were strongly abnormal. Although the N1-LEP 
(which we did not record) might have been more sensitive 
to disclose small latency delays, because both A-delta and 
C-LEPs were Absent or reduced in amplitude rather than 
being delayed, we believe that the small-fiber dysfunction 
originates from varicella-zoster-induced degeneration of 
the dorsal root ganglion cells. A relatively small increase in 
the latency of the R1 blink reflex may sometimes originate 
from an Aβ cell loss because of the reduced spatial-
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temporal summation at central synapses. Our patients, 
however, had strong delays (some had an R1 latency of 15–
20 ms), which are typical of demyelination [3,18]. Twelve 
patients had abnormal C-LEPs, and four abnormal A-δ 
LEPs, even after the stimulation of the non affected side. 
Eight of these patients were aged around 80 years. A 
previous study from our group found an age-related 
decrease in A-δ LEP amplitude [30]. Our findings in this 
study now suggest an age related decrease also for C-LEPs. 
LEP abnormalities after stimulation of the normal side 
possibly depend on mild neuronal loss or dysfunction in 
the peripheral nerves or in the brain with advancing age 
[13]. Another important point in interpreting our findings 
is that all our patients were receiving drugs acting on the 
nervous system that can dampen LEPs [4]. Alternatively, 
the bilaterally Abnormal finding may reflect bilateral 
dysfunction analogous to the bilateral Abnormality in 
EMG recordings [14], quantitative somatosensory testing 
[15] and neuropathological studies [33] in some patients 
with unilateral herpes zoster. The occurrence of these 
bilateral Abnormalities restricts the specificity of 
66 
 
neurophysiological testing to 71%; however, the sensitivity 
was high (93%), and thus neurophysiological testing 
would be useful in diagnosing zoster sine herpete.  
 
5.2. Pathophysiology of pain in PHN 
Whereas our patients’ neurophysiological abnormalities 
correlated with the severity of pain, their clinical sensory 
deficits did not, presumably because neurophysiological 
investigations are more accurate and objective in assessing 
nerve fiber damage than patients’ subjective reports of 
sensory deficits. An interesting finding concerns the 
clinical-neurophysiological correlations for the 
spontaneous pain, that patients with PHN typically 
describe as a constant, aching, burning pain. In our 
patients we found that the intensity of constant pain 
correlated with LEP abnormalities  related to A-delta and 
C-fibers, thus suggesting that the constant pain is related to 
thermal-pain pathway damage. This finding is in line with 
several clinical studies reporting that in patients with PHN 
constant pain is associated with heat pain deficits [10]. It 
also agrees with skin biopsy studies in patients with 
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constant pain reporting a severe loss of epidermal-free 
nerve endings [23,24]. In patients with PHN the loss of 
small ganglion neurons may provoke long-term changes in 
the central nervous system, including hyperactivity of the 
second-order neurons of the nociceptive pathway [10]; 
such hyperactivity of dorsal horn cells has been reported in 
animal studies following complete primary afferent loss of 
a spinal segment [19]. We cannot, however, completely 
rule out that only very few surviving and sensitized C 
nociceptors may induce constant pain. Besides constant 
pain, patients with PHN usually complain of paroxysmal 
pain, described as electrical shock like, shooting or 
stabbing pains. The correlation of paroxysmal pain with 
blink reflex abnormalities in our patients indicates that 
paroxysmal pain is associated with A-beta-fiber 
dysfunction. Our results agree with the previous animal 
studies reporting an increased spontaneous ectopic 
discharge recorded in sensory myelinated axons after 
nerve injuries [2]. These results suggest that paroxysmal 
pain may be related to high-frequency discharges of 
impulses abnormally generated in demyelinated  A-β 
68 
 
fibers. Whether the high-frequency bursts in demyelinated 
A-β fibers are sufficient to provoke pain per se or rather 
after ephaptic transmission to the neighboring C-fibers [1], 
or through a WDR neuron involvement [8] is still an open 
matter. We found no significant correlation of 
neurophysiological abnormalities with mechanical 
allodynia (too few patients had cold allodynia). It has been 
suggested that the incidence of allodynia may correlate 
inversely with the severity of small-fiber or spinothalamic  
deafferentation [25], i.e., that patients with allodynia tend 
to have higher LEPs than those without provoked pain 
[11]. In this report, the intensity of constant pain correlated 
with LEP attenuation, while that of provoked pain did not, 
which may in part support these assumptions. Probably 
this type of pain arises through multiple mechanisms and 
their relative contributions to pathophysiology  of 
mechanical allodynia differ among subjects and may vary 
over the course of PHN [10]. 
Because the correlation between the severity of itching and 
the C-LEP perceptive threshold and amplitude asymmetry 
only approached the statistical significance, we cannot 
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draw reliable lines of reasoning on the pathophysiological  
mechanism of itching in PHN. Whereas our C-LEPs reflect 
general damage to unmyelinated fibers, many studies 
showed that itching is specifically mediated by C-
pruriceptors [17,26]. Our study in a broad spectrum of 
patients with trigeminal PHN provides evidence that PHN 
impairs non-nociceptive as well as nociceptive trigeminal 
fibers. 
The correlation between specific fiber damage and the 
various clinical types of pain indicates that PHN pain 
arises through several distinct pathophysiological 
mechanisms.  
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Chapter 4: Differential involvement of Aδ and Aβ fibers 
in neuropathic pain related to carpal tunnel syndrome. 
  
Chapter based on: Differential involvement of Ad and Ab fibres in 
neuropathic pain related to carpal tunnel syndrome. A. Truini, L. 
Padua, A. Biasiotta, P. Caliandro, C. Pazzaglia , F. Galeotti, M. 
Inghilleri, G. Cruccu. PAIN 145 (2009) 105–109 
 
1. Introduction 
Carpal tunnel syndrome (CTS), an entrapment neuropathy 
of  the median nerve at the wrist [5], frequently manifests 
with neuropathic pain [12]. The commonly used test for 
diagnosing CTS is nerve conduction study (NCS) because 
it identifies and quantifies damage to the median nerve 
[17]. NCS nevertheless has the disadvantage of assessing 
non-nociceptive large myelinated fibres (Aβ-fibres) alone 
and provides no information on nociceptive fibre function 
[11]. Clinical assessment of patients with neuropathic pain 
relies on psychometric measures such as pain 
questionnaires. The clinician administered DN4 
questionnaire is a 10-item screening tool that indicates 
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neuropathic pain when the score is ≥4 [8]. The self-
administered neuropathic pain symptom inventory (NPSI) 
measures the intensity of the various qualities of 
neuropathic pain [7]. Current neurophysiological 
assessment of neuropathic pain relies on recording laser-
evoked potentials (LEPs) [14]. Laser generated radiant heat 
pulses selectively activate Aδ and C mechanothermal 
nociceptors, and evoke scalp potentials related to small 
myelinated (Aδ) fibres [31]. LEPs are the most reliable and 
agreed methods of investigating nociceptive fibre function 
in patients with pain [11]. A simpler neurophysiological 
tool for acquiring information on nociceptive fibre function 
is the cutaneous silent period (CSP), an inhibitory response 
evoked in hand muscles by painful digital nerve 
stimulation [30]. Although the CSP is used to investigate 
nociceptive Aδ-fibre function in the upper limb, its 
nociceptive origin remains controversial [16]. Even though 
CTS is a common peripheral nerve disorder, no studies 
have investigated the role of nociceptive and non-
nociceptive fibres in CTS-related neuropathic pain. We 
designed this prospective clinical and neurophysiological 
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study to gain more information on the frequency, quality 
and underlying mechanisms of CTS-related neuropathic 
pain. To investigate the different pathways involved in the 
development of pain we studied non-nociceptive Aβ-fibre 
function by standard nerve conduction study and 
nociceptive Aδ-fibre function by LEPs and CSP. We then 
determined the possible correlations between 
neurophysiological data and the various qualities of pain, 
as assessed by the NPSI. 
 
2. Methods 
2.1. Clinical examination 
We conducted a prospective study from December 2006 to 
June 2007 recruiting consecutive patients with CTS from 
two university neurological outpatient clinics. Seventy 
patients, aged 25–81 years (mean 54 years; 8 males, 62 
females), corresponding to 117 hands with CTS were 
enrolled in the Department of Neurological Sciences,  
Sapienza University, and in the Department of 
Neurosciences, Catholic University, both in Rome. One 
staff member examined the patients clinically and 
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administered the questionnaires and another did 
neurophysiological testing. The physician who assessed 
the results of neurophysiological testing was blinded to 
clinical findings and questionnaire results. All patients 
gave their informed consent to undergo the procedure. The 
research was approved by the two local Ethical 
Committees. The CTS diagnosis was based on established 
criteria and recommendations of the American Academy of 
Neurology (AAN) and the American Association of 
Electrodiagnostic Medicine (AAEM) [1,17]. The patient’s 
history was recorded and a complete neurophysiological 
examination was performed to exclude the presence of 
other diseases that could cause or contribute to CTS, such 
as diabetes, polyneuropathy, hypothyroidism or 
acromegaly. We included only patients with idiopathic 
CTS. The Boston Carpal Tunnel Questionnaire was used to 
obtain a patient-oriented validated measurement [24]. In 
brief, it evaluates two CTS domains: ‘‘symptoms” assessed 
on an 11-step scale; and ‘‘functional status” assessed on an 
8-step scale. The DN4 questionnaire for neuropathic pain 
was administered to all patients, for each hand separately. 
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Patients who scored ≥4 on the DN4 completed the NPSI 
questionnaire. The NPSI subscores were calculated for the 
five clinical symptoms: constant burning (superficial), 
constant pressing (deep), paroxysmal, provoked pain 
(allodynia, hyperalgesia) and abnormal sensations 
(paresthesias and dysesthesia). Although many patients 
had some kind of neuropathic pain complaint, only 4 were 
taking drugs (pregabalin and amitriptyline or duloxetine). 
 
2.2. Neurophysiological examination 
For nerve conduction testing we used a protocol inspired 
by the AAN and AAEM recommendations [1,17]. In brief, 
the testing comprised median nerve sensory conduction 
velocity in the Ist and IIIrd digit-wrist segments and ulnar 
nerve sensory conduction velocity in the Vth digit. Subjects 
who had normal median nerve sensory conduction 
velocities underwent the comparative test radial -median 
nerve sensory conduction velocity [27]. Motor nerve 
conduction was studied by stimulating the median and 
ulnar nerves at the wrist and the elbow and recording from 
thenar muscles and abductor digiti minimi. From the nerve 
80 
 
conduction study results CTS hands were classified into six 
severity groups: extreme, absent motor and sensory 
responses; severe, absent sensory response and abnormal 
distal motor latency; moderate, abnormal digit- wrist 
sensory nerve conduction velocity and abnormal distal 
motor latency; mild, abnormal digit-wrist sensory nerve 
conduction velocity and normal distal motor latency; and 
minimal, abnormal comparative test only. For the CSP 
study the IIIrd and Vth digits were stimulated with 
electrical shocks (80 mA, 0.5 ms) delivered through ring 
electrodes. Electromyographic (EMG) signals were 
recorded from the abductor digiti minimi muscle through 
surface electrodes. During EMG recordings, subjects were 
instructed to maintain an approximately maximum 
voluntary isometric contraction of the target muscle with 
the aid of EMG acoustic and visual feedback. Signals were 
samplified (bandwidth 50 Hz–5 kHz), full-wave rectified, 
averaged (6 trials) and stored. Onset and offset latency 
measurements were taken at the initial and final 
intersections of the averaged signal and a baseline 
indicating 80% of the background EMG level [16]. 
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In accordance with the recommendations of the 
International Federation of Clinical Neurophysiology 
(IFCN) [21], instead of measuring CSP suppression, we 
measured its duration, a CSP variable that depends less on 
background muscle contraction levels. To study LEPs we 
used a neodymium:yttrium–aluminium– perovskite 
(Nd:YAP) laser (wavelength 1.34 mm, pulse duration 2–20 
ms, maximum energy 7 J). The median nerve territory on 
the palm of the hand was stimulated by laser pulses at 
relatively high intensity (119–178 mJ/mm2), short duration 
(5 ms), and small diameter (5 mm) eliciting pinprick 
sensations. The laser beam was shifted slightly after each 
stimulus. The interstimulus interval was varied 
pseudorandomly (10–15 s). Subjects lay on a couch and 
wore protective goggles. They were instructed to keep 
their eyes open and gaze slightly downwards. To 
determine the laser perceptive threshold we delivered a 
series of stimuli at increasing and decreasing intensity, and 
defined the perceptive threshold as the lowest intensity at 
which the subjects perceived at least 50% of the stimuli. 
The main A-delta LEP complex, N2–P2, was recorded 
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through disc electrodes from the vertex (Cz) referenced to 
the nose. From 10 to 20 trials devoid of artefacts were 
collected and averaged offline. We measured peak latency 
and amplitude (peak-topeak) of the main N2–P2 vertex 
complex. We analyzed the correlation between the main 
neurophysiological data (IIIrd digit-sensory action 
potential and IIIrd digit-sensory nerve conduction velocity, 
IIIrd digit CSP duration, and LEP amplitude) and the five 
NPSI subscores (burning, pressing, paroxysmal, provoked 
pain and Abnormal sensations). 
 
3. Statistical analysis 
Non-parametric Mann–Whitney test was used to analyze 
the differences in clinical, demographic and 
neurophysiological data between painful and non-painful 
CTS hands. Chi-square test was used to assess the 
frequency of the various qualities of neuropathic pain, and 
frequency differences in CTS score severity between the 
painful and non-painful CTS hands. Correlations between 
neurophysiological data (IIIrd digit-sensory nerve action 
potential and conduction velocity, IIIrd digit CSP duration, 
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and LEP amplitude) and the NPSI score related to the five 
clinical symptoms (burning, pressing, paroxysmal, and 
provoked pain and abnormal sensations) were calculated 
with the non-parametric Spearman’s R correlation 
coefficient and P values adjusted with Bonferroni 
correction for multiple correlations. P values of <0.01 were 
considered significant. We reported in the text both P 
values (i.e. before and after Bonferroni correction) only for 
the variables that were significant after the correction. All 
data are reported as means ± SD. 
 
4. Results 
4.1. Clinical results 
Of the 117 hands from the 70 patients with CTS examined, 
the DN4 questionnaire identified 76 hands with 
neuropathic pain, and 41 without. No differences were 
found for age and Boston Carpal Tunnel Questionnaire 
scores between pain and non-pain groups (P > 0.2, Mann–
Whitney test) (Table 1). NPSI analysis showed that 51 CTS 
hands had burning pain (mean rating 3.5 ± 3.2), 42 pressing 
pain (mean rating 2.5 ± 2.6), 56 paroxysmal pain (mean 
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rating 3.1 ± 2.5), 39 provoked pains (mean rating 2.0 ± 3.6), 
and 62 Abnormal sensations (5 ± 3.3). The various kinds of 
pain differed significantly in frequency (P = 0.0002, chi-
square test), provoked pains being less frequent than 
paroxysmal pain and abnormal sensations. 
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Painful hands (n = 76) 
Non-painful hands (n = 41) 
Age (years) 54.3 ± 13.4 54.7 ± 15.8 
IIIrd digit SNAP amplitude (µV) 13.1 ± 9.3 15.3 ± 10.0 
IIIrd digit SNCV (m/s) 38.9 ± 7.3 40.5 ± 8.0 
IIIrd digit CSP duration (ms) 51.2 ± 17.8 49.0 ± 14.3 
Laser perceptive threshold (mJ/mm2)* 75.7 ± 24.9 55.7 ± 16 
N-LEP latency (ms) 190.5 ± 16.7 190.5 ± 14.6 
LEP amplitude (µV)** 10.6 ± 8.4 15.9 ± 5.9 
 
CTS: carpal tunnel syndrome; Min: minimal; Mild; Mod: 
moderate; Sev: severe; 
Ext: extreme; SNAP: sensory nerve action potential; SNCV: 
sensory nerve conduction 
velocity; CSP: cutaneous silent period; LEP: laser-evoked 
potentials. 
* P = 0.004. 
** P = 0.002. 
 
     Table 1. Summary  of clinical and neurophysiological data 
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4.2. Neurophysiological results 
Of the 117 hands from the 70 patients with CTS tested, the 
median nerve sensory action potential was Absent in 15 
CTS hands, the CSP in three (all patients who had extreme 
CTS, two with pain and one without). LEPs were absent in 
15 CTS hands (14 with pain and one without). No 
difference was found in the frequency of the different CTS 
severity grades between neuropathic and non-neuropathic 
groups (P = 0.13, chi-square test). Neither NCS data nor 
CSP duration differed between patients with and without 
pain (P > 0.2, Mann–Whitney test). Nor did the LEP latency 
differ between the two groups of patients (P > 0.2) but the 
perceptive threshold was higher and the LEP amplitude 
lower in CTS hands with pain than in those without (P = 
0.004 and P = 0.002) (Fig. 1).  
 
4.3. Pain correlations 
The NPSI subscores related to burning and pressing pain 
correlated only with LEP amplitude (burning pain: R = -
0.5036, P = 0.0004, after Bonferroni correction P = 0.008; 
pressing pain: R = -0.5311, P < 0.0001, after Bonferroni 
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correction P = 0.002; other neurophysiological variables P > 
0.1, Spearman’s R correlation coefficient). Conversely, the 
NPSI subscores related to paroxysmal paroxysmal pain 
and to Abnormal sensations correlated only with median  
nerve sensory conduction velocity (paroxysmal pain: R = -
0.5022, P < 0.0001; after Bonferroni correction P = 0.002; 
abnormal sensations: R = -0.4292, P = 0.0003; after 
Bonferroni correction P = 0.006; other neurophysiological 
variables P > 0.1) (Fig. 2). We found no significant 
correlation between the NPSI subscores related to 
provoked pain and any of the neurophysiological variables 
tested (P > 0.5). 
 
5. Discussion 
Our prospective clinical and neurophysiological study 
provides new information on the frequency, quality, and 
pathophysiological mechanisms underlying neuropathic 
pain in a large cohort of patients with CTS. A previously 
unreported finding is that median nerve conduction 
abnormalities, reflecting non-nociceptive Aβ-fibre damage, 
correlated with paroxysmal pain and abnormal sensations. 
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Conversely LEP abnormalities, reflecting nociceptive Aδ-
fibre damage, correlated with burning and pressing pain. 
  
5.1. Clinical findings 
The 65% frequency of neuropathic pain, as assessed by the 
DN4 questionnaire in our 117 patients with CTS is in line 
with the 50% reported in a previous clinical study in 1123 
patients with CTS assessed with a dichotomous categorical 
score (yes or no) [27]. A distinctive feature of our study is 
that we analyzed the various clinical qualities of 
neuropathic pain in CTS. This analysis, according to the 
NPSI, showed that provoked pains, including hyperalgesia 
and allodynia, are less frequent and less severe than  
paroxysmal pain, and abnormal sensations in patients with 
CTS. Given that patients with and without CTS-related 
pain had similar disease severity and similar Boston Carpal 
Tunnel Questionnaire scores we agree with others that 
pain related to CTS depends on factors other than disease 
severity [27]. 
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Fig. 1. Neurophysiological assessment in a representative CTS 
hand with (right) and without pain (left). (A) sensory nerve 
action potential (SNAP) after IIIrd digit stimulation. 
Calibration: 2 ms/10 µV. (B) cutaneous silent period (CSP) after 
IIIrd digit stimulation. Calibration: 50 ms/100 µV. (C) laser-
evoked potentials (LEPs) after median nerve territory 
stimulation. Calibration: 200 ms/10 µV. While SNAP latency 
and amplitude and CSP duration were similar in the two CTS 
hands, in the CTS hand with pain (predominantly burning 
pain) LEPs were absent. 
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Fig. 2. Correlations between neurophysiological abnormalities 
and pain. The  intensity of spontaneous burning pain (A) and 
spontaneous pressing pain (B) correlated with the A-delta LEP 
amplitude (R = -0.5036, P = 0.008; R = -0.5311, P = 0.002). The 
intensity of paroxysmal pain (C) and abnormal sensations (D) 
correlated with the median nerve sensory conduction velocity (R 
= -0.5022, P = 0.002; R = -0.4292, P = 0.006). Dashed lines indicate 
95% confidence intervals from the mean. 
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5.2. Neurophysiological findings 
The CSP was absent only in 3 of the 117 hands we tested, 
all from patients who had extreme CTS and absent LEPs. 
Several studies reported that in severe entrapment 
neuropathies the CSP, a response mostly mediated by A-
delta fibres, is usually spared and is abolished only by 
complete nerve transection [30], probably because 
compression mainly damages large myelinated fibres, and 
tends to spare small fibres [25]. Our data confirm that the 
CSP is a useful tool for documenting residual nerve 
continuity in severe entrapment neuropathies [30]. 
Although LEPs are usually recorded after applying stimuli 
to hairy skin, a recent study, using the same type of laser 
stimulator, showed that laser stimuli applied to glabrous 
and hairy skin yield similar psychophysical and 
electrophysiological responses [15]. Whereas LEP 
amplitude differed in CTS hands with and without pain, 
CSP did not. These findings support the view that LEPs are 
highly sensitive to nociceptive pathway impairment and 
the most reliable diagnostic tool for neuropathic pain [11]. 
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Conversely, rather than being a pure nociceptive response 
the CSP may also have an Aβ-fibre-mediated component 
[29]. Accordingly, it is not suppressed by opiates given at a 
dose that induces pain relief and suppresses the 
nociceptive RIII reflex in the biceps femoris muscle [16], 
and does not correlate with pain in patients with 
peripheral neuropathy [32]. 
 
5.3. Pain correlations 
We found that superficial burning and deep pressing pain 
correlated inversely with LEP amplitude, thus suggesting 
that these types of pain are due to nociceptive pathway 
damage. Our data are in line with previous studies that 
found a close link between pain and nociceptive fibre 
damage in painful polyneuropathy as assessed by 
psychophysiological [22], neurophysiological [10], or 
neuropathological (skin and nerve biopsies) [20,34] 
investigations in patients with different types of peripheral 
neuropathy. Therefore CTS and polyneuropathy share 
similar pathophysiological mechanisms underlying 
ongoing pain. Animal studies demonstrated that 
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peripheral nerve injury causes spontaneous 
hyperexcitability of nociceptive afferents (peripheral 
sensitization) [13,19,35]. Microneurographic studies in 
humans reported that in patients with peripheral 
neuropathies burning pain is associated with spontaneous, 
anomalous discharges in afferent fibres [6,26]. We therefore 
hypothesize that in patients with CTS spontaneous 
constant pain arises from abnormal, spontaneous 
hyperactivity originating in damaged axons of nociceptive 
fibres. However, we cannot exclude the possibility that 
nociceptive pathway damage may provoke long-term 
changes in the central nervous system, including 
hyperactivity of the second order neurons of the 
nociceptive pathway (central sensitization) [13,23,28] that 
may act as a concurrent mechanism. The NPSI items 
corresponding to paroxysmal pain, and abnormal 
sensations correlated with sensory nerve conduction 
velocity, thus indicating that these sensory disturbances 
are associated with Aβ-fibre damage. This finding confirms 
the notion that paresthesias and non-painful sensory 
disturbances are caused by abnormal non-nociceptive A-
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beta-fibre activity [18]. The mechanisms responsible for 
paroxysmal pain are far more controversial. In particular 
CTS is a condition characterised by chronic focal 
compression that induces demyelination, which mainly 
affects Aβ-fibres [25]. Our finding of a correlation between 
Aβ-fibre damage and paroxysmal pain is therefore 
coherent with the pathophysiological mechanisms of CTS. 
However, in an earlier study we found that also in patients 
with postherpetic neuralgia paroxysmal pain was 
associated with delayed Aβ-fibre-mediated responses [33]. 
These data raise the possibility that regardless of the 
disease paroxysmal pain may be invariably related to Aβ-
fibre damage. Consistently with previous animal studies 
describing spontaneous ectopic discharges recorded in Aβ-
fibre axons after nerve injuries [2,3,9], we suggest that 
paroxysmal pain is related to high frequency bursts 
generated in demyelinated Aβ-fibres. Whether these high-
frequency bursts in demyelinated Aβ-fibres are sufficient 
to provoke pain per se or do so only after ephaptic 
transmission to the neighbouring C fibres, or through the 
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involvement of wide dynamic range neurons is an open 
matter [33]. 
NPSI item related to provoked pains correlated with none 
of the neurophysiological data. Many studies proposed 
alternative mechanisms for allodynia/hyperalgesia. 
Provoked pains may arise through multiple mechanisms 
even in the same disease (and may vary over the course of 
disease), thus their relative contributions may differ among 
subjects [13]. 
Our study shows that a specific type of neuropathic pain is 
differentially associated with nociceptive and non-
nociceptive fibre damage and thus arises through different 
pain mechanisms. If these findings hold true in other 
neuropathic pain conditions, showing that the various 
types of neuropathic pain are invariably caused by similar 
mechanisms regardless of the disease, they could be useful 
in designing new treatment strategies targeted to the type 
of pain [4]. 
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Chapter 5: Mechanisms of pain in multiple sclerosis: a 
combined clinical and neurophysiological study 
 
Chapter based on: Mechanisms of pain in multiple sclerosis: a combined 
clinical and neurophysiological study.  A Truini, F Galeotti, S La Cesa, 
S Di Rezze, A Biasiotta, G Di Stefano, E Tinelli, E Millefiorini, A 
Gatti, G Cruccu. Pain. In press 
 
Introduction 
Neuropathic pain is common in patients with multiple 
sclerosis (MS). According to previous published studies its 
prevalence ranges from 26% to 58% [17,18]. Although MS 
patients may suffer from various types of neuropathic 
pain, the most frequent are the ongoing extremity pain and 
the Lhermitte’s phenomenon [18]. Ongoing extremity 
pain—often called “dysesthetic extremity pain” in the MS 
literature [17]—is a chronic form of pain in MS patients 
[18,19], described as a continuous burning pain that is 
typically bilateral, affecting the legs and feet, and that is 
usually worse at night. Lhermitte’s phenomenon is defined 
as a transient short-lasting sensation related to neck 
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movement and felt in the back of the neck, lower back or in 
other parts of the body [1,18]. Clinical assessment of 
patients with neuropathic pain relies on psychometric 
measures such as pain questionnaires. The clinician-
administered DN4 questionnaire is a 10-item screening tool 
that indicates neuropathic pain when the score is 4 [5]. 
Electrically-elicited somatosensory evoked potentials 
(SEPs) are commonly used in patients with sensory 
disturbances due to multiple sclerosis [23]. SEPs are 
mediated by non-nociceptive Aβ-fibres, the afferent input 
is relayed through the dorsal columns of the spinal cord 
and the medial lemniscus in the brainstem, and provide no 
information on nociceptive pathways, [7,26].  The most 
reliable and agreed neurophysiological method for 
investigating nociceptive fibre function in patients with 
neuropathic pain is laser evoked potential (LEP) recording 
[7,11]. Laser-generated radiant heat pulses selectively 
activate Aδ and C mechano-thermal nociceptors [26], and 
evoke scalp potentials related to small myelinated (Aδ) 
fibres. The afferent volley is conducted along small-
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myelinated (Aδ) primary sensory neurons, and relayed to 
ascending nociceptive spinal pathways and brain [7,9,26].  
Although patients with multiple sclerosis frequently 
experience neuropathic pain, effective treatment awaits 
research clarifying the underlying mechanisms. In this 
clinical and neurophysiological study we sought 
information on the clinical characteristics and the 
underlying mechanisms of the two commonest types of 
neuropathic pain related to multiple sclerosis: ongoing 
neuropathic pain and Lhermitte’s phenomenon. To do so 
we collected MS patients, and identified by clinical 
examination and DN4 questionnaire patients with the 
different types of neuropathic pain. Then to assess 
nociceptive and non-nociceptive pathway function in these 
two types of neuropathic pain we investigated SEPs and 
LEPs. 
 
Methods 
We conducted a period prevalence study collecting 
consecutive patients with a definite diagnosis of multiple 
sclerosis from the outpatient clinic at the Department of 
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Neurology and Psychiatry at Sapienza University, Rome. 
Patients with a clinical isolated syndrome (patients 
presenting with acute or subacute episode of neurological 
disturbance due to a single white-matter lesion [16]) were 
also included. Two neurologists (one from the multiple 
sclerosis outpatient service and the other from the 
neuropathic pain unit) examined the patients clinically and 
administered the questionnaire, and two 
neurophysiologists performed the evoked potential 
recordings. All patients gave their informed consent to 
undergo the procedure. The research was approved by the 
Institutional Review Board.  
 
Clinical examination 
All patients underwent a detailed neurological 
examination using bedside tools. Touch was investigated 
with a piece of cotton wool and von Frey hairs, vibration 
with a tuning fork (128 Hz), pinprick sensation with a 
wooden cocktail stick. In all patients laser stimuli were 
used for a quantitative evaluation of warm and pinprick 
sensations. The diagnosis of multiple sclerosis was based 
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on Polman criteria [20]. In all patients the expanded 
disability severity score (EDSS) was collected to rate the 
severity of multiple sclerosis. Patients were asked to report 
pain experienced within one month of assessment. Being 
too difficult to ascertain its causal or casual association 
with MS, headache alone was not considered. All patients 
with pain other than headache completed the DN4 
questionnaire for neuropathic pain. In every patient a 
definite diagnosis of neuropathic pain was supported by 
the patient history, the clinical examination (including the 
DN4) showing the positive and negative sensory signs 
with a logical neuroanatomical distribution and laboratory 
tests (MRI and neurophysiological testing) [27]. We then 
divided patients into three groups: without pain, with 
nociceptive pain, and neuropathic pain. Patients were 
instructed to rate pain intensity on an 11-point numerical 
rating scale ranging from 0 (no disturbance) to 10 (worst 
possible disturbance). 
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Neurophysiological testing 
We studied somatosensory evoked potentials after median 
and tibial nerve stimulation using surface recording 
electrodes with standard placement. Methods used 
adhered to those recommended by experts of the 
International Federation of Clinical Neurophysiology [7]. 
In brief, electrical stimuli were applied to the median and 
tibial nerve with saline-soaked pads at a frequency of 4 Hz 
(stimulus duration 0.1 ms; intensity: sensory plus motor 
threshold; bandpass: 10–1000 Hz). Early cortical 
somatosensory evoked potentials (N20 or P40) were 
recorded from Pc and Cz versus Fz, and two series of 1000 
artefact-free trials were averaged online for each nerve 
tested. To study laser evoked potentials we used a 
neodymium:yttrium–aluminium–perovskite (Nd:YAP) 
laser (wavelength 1.34 mm, pulse duration 2–20 ms, 
maximum energy 7 J). Foot and hand were stimulated by 
laser pulses at relatively high intensity (127–203 mJ/mm2), 
short duration (5 ms), and small diameter (5 mm) eliciting 
pinprick sensations. The laser beam was shifted slightly 
after each stimulus. The interstimulus interval was varied 
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pseudorandomly (10–15 s). Subjects lay on a couch and 
wore protective goggles. They were instructed to keep 
their eyes open and gaze slightly downwards. To 
determine the laser perceptive threshold we delivered a 
series of stimuli at increasing and decreasing intensity, and 
defined the perceptive threshold as the lowest intensity at 
which the subjects perceived at least 50% of the stimuli. 
The early, lateralized component, N1, and the main 
complex, N2–P2, were recorded through disc electrodes 
from the temporal areas (Tc) referenced to frontal area (Fz) 
and vertex (Cz) referenced to the nose. From 10 to 20 trials 
devoid of artefacts were collected and averaged offline. We 
measured peak latency and amplitude (peak-to-peak) of 
the temporal N1 component and the N2–P2 vertex 
complex.  In all patients median and tibial nerve 
somatosensory evoked potentials and hand and foot laser 
evoked potentials were recorded bilaterally and considered 
abnormal when stimulation applied to at least one limb 
yielded abnormal results. Neurophysiological data were 
compared with normative ranges in our laboratory [7]. 
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Statistical analysis 
One-way analysis of variance (ANOVA) was used to assess 
group differences for age, duration of disease in patients 
with neuropathic pain, nociceptive pain, and without pain. 
We used the non-parametric Kruskal-Wallis analysis to test 
group differences for pain intensity and EDSS. Mann-
Whitney test was used to compare the severity of 
neuropathic and nociceptive pain. Because age, duration of 
disease and EDSS might influence the development of pain 
in concert, a logistic regression analysis was used to assess 
which of these factors predict the development of pain. In 
the logistic regression analysis the three variables were 
divided in two groups according to the median value. 
Then data for patients without pain were compared with 
those for patients with nociceptive and neuropathic pain. 
We used the chi-square test to assess the differences in 
frequency of pain in the various clinical courses of multiple 
sclerosis, and the Fisher exact test for the 
neurophysiological abnormalities across ongoing extremity 
pain and Lhermitte’s phenomenon. P values of <0.05 were 
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considered to indicate statistical significance. All results 
are reported as means ± SD. 
 
Results 
We consecutively collected data for 302 patients (211 F, 91 
M, mean age 39.4 ± 10.9 years, mean EDSS: 2.0 ± 2.3; mean 
duration of disease from the diagnosis (years): 8.0 ± 7.2). In 
239 patients multiple sclerosis had a relapsing-remitting 
course, in 10 primary progressive, in 43 secondary 
progressive, and 10 patients had a clinical isolated 
syndrome. Of the 302 patients studied, 92 patients had 
pain (30%). According to clinical examination and DN4 
questionnaire 42 patients (13.9%) experienced neuropathic 
pain. The other patients suffered from back pain, muscle 
spasm, and other musculoskeletal pains. Of the 42 patients 
with neuropathic pain 8 had trigeminal neuralgia (2.6%), 
15 ongoing extremity pain (5.0%), and 19 Lhermitte’s 
phenomenon (6.3%).  The intensity of neuropathic pain did 
not differ from that of nociceptive pain (6 ± 1.9 vs 5.6 ± 1.4, 
P = 0.8, Mann-Whitney test). However Kruskall-Wallis 
analysis showed that trigeminal neuralgia was the most 
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severe type of pain, and the Lhermitte’s phenomenon the 
less severe (P <). Patients with trigeminal neuralgia had a 
paroxysmal, electrical shock-like sensation in the face, 
usually triggered by light mechanical touch. All these 
patients had a mild tactile hypoesthesia. Three patients 
also had an increased pinprick threshold to laser stimuli. 
Patients with ongoing extremity pain had ongoing, 
predominantly burning, pain mainly affecting the legs. All 
patients had thermal-pain sensory deficits as assessed by 
the laser perceptive threshold examination, and milder 
sensory deficits affecting touch and vibration sensations. 
Patients with Lhermitte’s phenomenon felt an electrical 
sensation, spontaneous or related to neck flexion, radiating 
down the spine and the limbs. Most patients with 
Lhermitte’s phenomenon had only mild deficit of touch 
and vibration sensations, affecting the distal part of the 
body. Notwithstanding the abnormalities of the MRI and 
neurophysiological testing four patients had no clinically 
evident sensory deficits, as assessed by bedside tools. Chi-
square test showed that neuropathic pain was less frequent 
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in patients with a clinical isolated syndrome and relapsing-
remitting form than the other clinical forms (P < 0.05).  
ANOVA showed that patients with pain (nociceptive and 
neuropathic) were older and with a longer duration of 
disease. Kruskall-Wallis analysis showed that patients with 
pain (nociceptive and neuropathic) had a higher EDSS and 
a longer duration of disease (P < 0.0001). Logistic 
regression analysis identified EDSS as the only factor 
significantly associated with neuropathic pain (OR 2.3; CI 
95%:1.1-4.9; P = 0.03).   
Ten patients with ongoing extremity pain and 18 with 
Lhermitte’s phenomenon underwent neurophysiological 
testing. SEPs were abnormal in 3 out of 10 patients with 
ongoing extremity pain (30%) and in 13 out of 18 patients 
with Lhermitte’s phenomenon (72%)(Figure 1,2). 
Conversely, LEPs were abnormal in 9 patients with 
ongoing extremity pain (90%) and in 3 patients with 
Lhermitte’s phenomenon (16.6%) (Figure 1,2). Whereas the 
abnormality frequency of SEPs was significantly higher in 
patients with Lhermitte’s phenomenon (P = 0.002, Fisher 
exact test), the abnormality frequency of LEPs was 
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significantly higher in patients with ongoing extremity 
pain (P = 0.02) (Figure 3). In all patients with ongoing 
extremity pain and most of those with Lhermitte’s 
phenomenon magnetic resonance imaging (MRI) showed a 
spinal lesion. In most cases MRI scans could not precisely 
distinguish whether the lesion involved the anterolateral or 
the dorsal columns. The eight patients with trigeminal 
neuralgia did not undergo the evoked potential testing 
because of the low number and the peculiarities of the 
trigeminal system.  
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Figure 1. Spinal MRI and neurophysiological assessment in 
ongoing extremity pain.  MRI scans shows demyelinating 
lesions affecting thoracic spinal cord in a patient with ongoing 
extremity pain. In this patient while somatosensory evoked 
potentials (SEPs) were spared, laser evoked potentials (LEPs) 
after foot stimulation were absent. LEPs: 20µV/200ms. Median 
nerve SEPs: 4µV/5ms; Tibial nerve SEPs: 4µV/10ms   
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 Figure 2. Spinal MRI and neurophysiological 
assessment in Lhermitte’s phenomenon.  MRI scans 
shows a demyelinating lesions affecting cervical spinal 
cord in a patient with Lhermitte’s phenomenon. In this 
patient while LEPs were spared, SEPs after median and 
tibial nerve stimulation were absent. LEPs: 
20µV/200ms. Median nerve SEPs: 4µV/5ms; Tibial 
nerve SEPs: 4µV/10ms. 
 
116 
 
 
Figure 3. Prevalence of the neurophysiological Abnormalities 
in patients with in ongoing extremity pain and Lhermitte’s 
phenomenon.  A: Graph showing that in patients with ongoing 
extremity pain the abnormality frequency of LEPs was 
significantly higher than that of the SEPs (P = 0.02, Fisher exact 
test). B: Graph showing that in patients with Lhermitte’s 
phenomenon the abnormality frequency of the SEPs was 
significantly higher than that of the LEPs (P = 0.002, Fisher exact 
test). 
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Discussion 
In this period prevalence study in patients with 
neuropathic pain related to multiple sclerosis identified by 
clinical examination and responses to the DN4 
questionnaire, we found that a higher EDSS and a more 
severe clinical course (such as secondary and primary 
progressive) increase the risk of developing neuropathic 
pain. We also provide new neurophysiological evidence 
that ongoing extremity pain is associated with LEP 
abnormalities, thus suggesting that this type of pain arises 
from nociceptive pathway damage. Conversely, 
Lhermitte’s phenomenon is associated with SEP 
abnormalities, thus presumably arises from damage to the 
non-nociceptive Aβ-fibre pathway. 
 
Clinical findings 
The overall prevalence of pain assessed within the past 
month was 30% and that of neuropathic pain was 14%. 
Both values are lower than those (53-79% and 58% 
respectively) reported in previous studies [2,4,18,24]. These 
discrepant results probably depend partly on our patients’ 
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clinical characteristics given that our patients were 
younger, the EDSS was lower, the duration of disease was 
shorter and the clinical course less severe than those 
reported in the literature. Another possible explanation is 
that previous studies over-rated the prevalence of pain: 
according to a recent systematic review [18] studies on 
pain in MS frequently assessed the presence of pain only 
by a mail questionnaire, and some studies included any 
type of pain, nor did they use a validated questionnaire to 
diagnose neuropathic pain. The DN4 questionnaire that we 
used in our study, specifically designed to diagnose 
neuropathic pain, increases diagnostic specificity and thus 
reduces false-positive diagnoses, particularly for ongoing 
pain. DN4 is a validated screening tool to diagnose 
neuropathic pain with a high specificity and sensitivity 
(about 80%) [5]. However we also used clinical 
examination in addition to DN4 to identify patients with 
neuropathic pain because it might fail to identify patients 
with trigeminal neuralgia and Lhermitte’s sign. Indeed 
these patients frequently complain only of paroxysmal, 
electrical shock like sensations, and no other clinically-
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evident sensory disturbances or pains can be detected in 
the region affected by pain.  We found that patients with 
higher EDSS and a more severe clinical MS course 
(primary and secondary progressive courses) are at 
increased risk for the development of neuropathic pain. 
This finding is in line with several previous clinical studies 
and suggests that the more numerous the lesions the 
higher the probability of pain developing [18,22]. 
 
Neurophysiological findings and pain mechanisms  
We showed that a specific type of sensory disturbance was 
associated with a specific afferent pathway damage as 
assessed by neurophysiological testing. Previous 
neurophysiological studies have already investigated LEPs 
in patients with multiple sclerosis showing their high 
diagnostic sensitivity in patients with sensory disturbances 
[13,23]; however these studies have not analysed pain 
characteristics or investigated possible correlations 
between LEP abnormalities and pain. We found that 
ongoing extremity pain is associated with LEP 
abnormalities, thus suggesting that this type of pain is 
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related to nociceptive pathway damage. In all patients, 
MRI imaging showed cervical or thoracic spinal cord 
damage. Accordingly, we hypothesize that in our patients 
ongoing extremity pain arises from spinothalamic tract 
lesions. As the underlying mechanism we conjecture 
deafferentation of thalamic nuclei [9,12].  We found that 
Lhermitte’s phenomenon is associated with SEP 
abnormalities, thus suggesting that this type of pain is 
related to non-nociceptive A-fibre pathway damage. 
Because most patients had cervical spinal cord lesions as 
assessed by MRI imaging, and reported pain due to neck 
movement, Lhermitte’s phenomenon probably arises from 
a demyelinating lesion in the dorsal columns of the cervical 
spinal cord. This hypothesis is a common belief among 
clinicians [14,21], and has also been supported by a 
previous MRI study [10], but this is the first study 
confirming it with a functional investigation such as 
evoked potentials.  Our finding that Lhermitte’s 
phenomenon, a paroxysmal, electrical-shock-like sensation, 
is associated with dorsal column damage, is consistent 
with previous  neurophysiological studies in peripheral 
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neuropathic pain conditions (i.e. postherpetic neuralgia 
and carpal tunnel syndrome) showing that this type of 
pain is associated with A-fibre demyelination [27,28]. 
These data suggest that, regardless of aetiology, 
paroxysmal pain is related to Aβ-fibre damage. 
Consistently with previous animal studies describing 
spontaneous ectopic discharges recorded in Aβ-fibre axons 
after nerve injuries [6,15,29], we conjecture that paroxysmal 
pain is related to high-frequency bursts generated in 
demyelinated Aβ-fibres. Whether these high-frequency 
bursts in demyelinated Aβ-fibres are sufficient to provoke 
pain per se or do so only after ephaptic transmission to 
neighbouring nociceptive fibres, or by involving wide 
dynamic range neurons is an open matter. Our findings in 
patients with multiple sclerosis lend further support to the 
view that neuropathic pain should be classified according 
to sensory profiles rather than aetiology [3,8]. This 
approach could minimize the pathophysiological 
heterogeneity within study groups and clinical trials, thus 
making it easier to identify a positive treatment response 
and opening the way to new therapeutic approaches.  
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Chapter 6: Mechanisms of pain in distal symmetric 
polyneuropathy: A combined clinical,  
neurophysiological and morphological study. 
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1. Introduction 
Distal symmetric polyneuropathy is a common 
neurological  condition that has manifold causes, including 
systemic diseases, metabolic disorders, and exogenous 
toxic substances [17]. Sensory disturbances include 
hypaesthesia involving the various sensory modalities, and 
pain. Functional assessment of patients with neuropathic 
pain relies on psychometric measures, such as pain 
questionnaires and sensory testing, and dedicated 
neurophysiological tests. A validated and commonly used 
pain questionnaire is the self-administered Neuropathic 
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Pain Symptom Inventory (NPSI), a tool designed to 
measure the intensity of the various neuropathic pain 
qualities [5,26]. The reference standard test for diagnosing 
neuropathy is the nerve conduction study (NCS). NCS 
nevertheless has the disadvantage of assessing non-
nociceptive, large myelinated fibres (Aβ fibres) alone and 
provides no information on nociceptive pathway function 
[7]. Current neurophysiological assessment of nociceptive 
pathways relies on recording laser-evoked potentials  
(LEPs) [7]. Laser-generated radiant heat pulses selectively 
activate Aδ and C mechano-thermal nociceptors, and 
evoke scalp potentials  related to small myelinated (Aδ) 
fibres [29,30]. Although laser stimuli activate both Aδ and 
C mechano-thermal nociceptors, LEPs related to C-fibres 
cannot be reliably recorded after foot stimulation [7,30–32]. 
LEPs are the most reliable and agreed neurophysiological 
method for investigating nociceptive fibre function in 
patients with pain [7]. Although damage to small nerve 
fibres is widely assessed by quantifying  intraepidermal 
nerve fibres from a skin biopsy a recent study showed that 
intraepidermal nerve fibre density did not correlate with 
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neuropathic pain [10]. The pathophysiological mechanisms 
underlying neuropathic pain remain debatable. Although 
most investigators postulate that neuropathic pain always 
arises from nociceptive pathway damage [20,22], others – 
invoking the undeniable inhibitory effect of Aβ-fibre input 
on central nociceptive transmission [8,24] – have suggested 
that Aβ-fibre loss may provoke pain by disinhibiting 
nociceptive pathways [9,14]. An earlier study reporting 
that a pre-existing neuropathy selectively involving Aβ-
fibres is a risk factor for the development of chronic 
postherpetic pain [2] suggests that Aβ-fibre loss could be a 
contributing factor in this neuropathic pain condition. This 
pathophysiological mechanism receives further support 
from a recent clinical and neurophysiological study in 
patients with peripheral neuropathy showing that pain 
correlates with Aβ-fibre damage, as assessed with nerve 
conduction  studies (NCS) [19]. More information is 
therefore, needed  on pathophysiological mechanisms 
underlying neuropathic pain related to distal symmetric 
peripheral neuropathy. This information could be used to 
develop more effective therapeutic approaches for a pain 
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condition that is notoriously difficult to treat. We designed 
this clinical, neurophysiological and histomorphological 
study in patients with distal symmetric  polyneuropathy to 
investigate the role of clinical features, such as age and 
duration of disease, and the role of primary afferent 
neurons (non-nociceptive Aβ and nociceptive Aδ afferent 
fibres) on the development of neuropathic pain. We 
assessed clinical variables including the various qualities of 
neuropathic pain with the NPSI and non-nociceptive Aβ-
fibre function with standard nerve conduction study 
(NCS), nociceptive Aδ-fibre function with laser-evoked 
potentials (LEPs), and nociceptive C-fibre damage with 
skin biopsy and intraepidermal nerve fibres (IENF) 
quantification. 
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2. Methods 
We screened 2240 patients with sensory disturbances 
consecutively referred to our institution from October 2006 
to June 2011, and collected 269 patients with distal 
symmetric polyneuropathy (57% with pain and 43% 
without). The diagnosis of distal symmetric 
polyneuropathy was based on clinical, biological, and 
electrodiagnostic findings, adhering to the criteria 
proposed by England et al. [13]. Patients with symmetrical 
reduction or absence of ankle reflexes, decreased distal 
sensation, and abnormal NCS or LEPs were included in 
this study. Exclusion criteria were diagnosis of 
inflammatory or inherited neuropathies, sensory 
disturbances due to neurological diseases other than distal 
symmetric polyneuropathy, cognitive impairment. We 
chose to exclude patients with inflammatory or inherited 
neuropathies because these kinds of neuropathies seldom 
manifest with focal or multifocal sensory disturbances, and 
thus we decided to avoid a retrospective selection of this 
kind of patients. Aetiologies varied widely: chemotherapy-
induced neuropathy (50  patients), diabetic neuropathy (89 
132 
 
patients), peripheral neuropathy of unknown origin (51 
patients), monoclonal gammopathy-related neuropathy (79 
patients). All patients underwent clinical examination, a 
nerve conduction  study, LEP recordings and 69 of them  
skin biopsies with quantification of somatic IENFs. One 
staff member examined the patients clinically and 
administered the NPSI questionnaire and others did 
neurophysiological testing, with those recording NCS 
being blinded to LEP data and vice versa. The research was 
approved by  the local Ethical Committee. 
 
 
2.1. Clinical examination 
All patients underwent a detailed neurological 
examination using bedside tools. Touch was investigated 
with a piece of cotton wool, vibration with a tuning fork 
(128 Hz), and pinprick sensation with a wooden cocktail 
stick. In all patients laser stimuli were used for a 
quantitative evaluation of warm and pinprick sensations. 
Gait impairment, and muscle strength were assessed with 
the Medical Research Council score. Patients were also 
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asked to report dysautonomic symptoms. Patients were 
grouped according to the clinically documented presence 
or absence of neuropathic pain rated ≥4 on the 0–10 
numerical rating scale and persisting since at least one 
month [12]. All the patients with pain were taking pain 
medications: 40.5% was taking gabapentin or pregabalin, 
19.5% duloxetine, 10.5%  a combination therapy with 
pregabalin and duloxetine, 7.5% tramadol, 16.5% a 
combination of tramadol and pregabalin, 4.5%  oxycodon, 
and 3%  amytriptiline. Patients with pain completed the 
NPSI questionnaire. The NPSI subscores were calculated 
for the various types of pain: ongoing pain (burning and 
pressing pain), paroxysmal, provoked pain and abnormal 
sensations (paraesthesias and dysaesthesia). 
 
 
2.2. Neurophysiological examination and skin biopsy 
Patients underwent motor and sensory NCS using surface 
recording electrodes with standard placement. Methods 
used adhered to those recommended by experts of the 
International Federation of Clinical Neurophysiology [18]. 
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NCS comprised sensory nerve action potentials (SNAPs) 
and conduction velocities recorded from sural, ulnar and 
superficial radial nerves. Other nerve function variables 
examined were compound motor action potential (CMAP) 
amplitude and peroneal, tibial and ulnar nerve conduction 
velocities. To study LEPs, we used a neodymium:yttrium-
aluminium- perovskite (Nd:YAP) laser (wavelength 1.34 
mm, pulse duration 2–20 ms, maximum energy 7 J). The 
dorsum of the right foot and the left hand was stimulated 
by laser pulses at relatively high intensity (150–200 
mJ/mm2), short duration (5 ms), and small diameter (5 
mm) eliciting pinprick sensations. The laser beam was 
shifted slightly after each stimulus. The interstimulus 
interval was varied pseudo-randomly (10–15 s). Subjects 
lay on a couch and wore protective goggles. They were 
instructed to keep their eyes open and gaze slightly 
downwards. To determine the laser perceptive threshold, 
we delivered a series of stimuli at increasing and 
decreasing intensities, and defined the perceptive 
threshold as  he lowest intensity at which the subjects 
perceived at least 50% of laser stimuli. The early, 
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lateralized component, N1, and the main complex, N2–P2, 
were recorded through disc electrodes from the temporal 
areas (Tc) referenced to frontal area (Fz) and vertex (Cz) 
referenced to the nose. From 10 to 20 trials devoid of 
artefacts  were collected and averaged offline. We 
measured peak latency and amplitude (peak-to-peak) of 
the temporal N1 component and the N2–P2 vertex 
complex. NCS and LEP data were compared with 
normative ranges established in our laboratory. Patients 
underwent skin biopsies from the proximal region of the 
thigh (20 cm below the anterior iliac spine) and the distal 
region of the leg (10 cm Above the lateral malleolus, with 
the sural nerve territory). Biopsies were taken after local 
anesthesia using a 3 m disposable punch under sterile 
technique. Three sections randomly  chosen from each 
biopsy were immunoassayed with polyclonal anti-protein-
gene- product 9.5 antibodies using the free-floating 
protocol for bright field immunohistochemistry [19,20]. 
The linear density of  intraepidermal fibers was calculated 
following the rules reported by the guidelines of the 
European Federation of the Neurological Societies [21]. 
136 
 
IENF data were compared with normative ranges 
established in our laboratory. 
 
2.3. Statistical analysis 
We used Mann–Whitney U-test to analyze the differences 
in neurophysiological and clinical data between patients 
with and without pain. Chi-square test was used to assess 
the frequency of the various qualities of neuropathic pain 
across the different aetiologies. We used the nonparametric 
Spearman’s R correlation coefficient to correlate the 
intensity of ongoing and provoked pain, the most frequent 
qualities of pain,  with foot-LEP amplitude, IENF density, 
and the intensity of Abnormal sensations with sural-SNAP, 
conduction velocity from sural nerve and foot-LEP 
amplitude. P values of <0.05 were considered significant. 
All results are reported as means ± SD. 
 
3. Results 
Of the 269 selected patients, all having distal, symmetric 
sensory disturbances mostly had a predominantly sensory 
neuropathy and 153  had pain . Whereas delay since 
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symptom onset was longer in patients with pain than in 
those without (3.8 ± 3.1 years vs 2.3 ± 1.7; P = 0.01, Mann–
Whitney test), no difference was found between the two 
groups in age (65.2 years vs 63.6 years; P > 0.30) (Table 1). 
Although clinical assessment showed that most patients, 
regardless of pain, had sensory deficits involving all 
sensory modalities, pinprick and thermal thresholds 
assessed with laser stimuli were significantly higher in 
patients with pain than in those without (P < 0.001). Nine 
patients (seven with pain, two without) had an increased 
laser perceptive threshold but a clinically normal pinprick 
sensation.  
No difference was found in the frequency of neuropathic 
pain and its different qualities between the various 
aetiologies (P > 0.5, χ2-test). NPSI analysis showed that 
nearly all patients had ongoing pain: 119 had burning pain 
(mean rating 6.9 ± 2.0). Of the  153 patients with pain 63  
had also provoked pain (mean rating 5.8 ± 3.8) (Table 2). 
The various kinds of pain differed significantly in 
frequency (P < 0.0001, χ2-test), burning pain being more 
frequent and severe than the other types of pain. Patients 
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with provoked pain had lower pinprick and thermal laser 
thresholds than patients with ongoing pain (P < 0.0001, 
Mann–Whitney test).  
Whereas LEP amplitude (both the N1 component and the 
N2–P2 complex) significantly differed between patients 
with and without pain (P < 0.0001), NCS and IENF density 
data did not (P > 0.50) (Fig. 1A, 1B and 2); nor did LEP 
latency and sensory conduction velocities differ in the two 
groups. All patients with distal symmetric neuropathy 
showed loss of intraepidermal nerve fibers (Table 1 and 
Fig. 1B). 
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Clinical data 
Age (years) 63.6 ± 11.1 65.2 ± 9.1 
Delay since symptom onset (years)  2.3 ± 1.7 3.8 ± 3.1* 
Warm threshold after hand stimulation (mJ/mm2) 37.3 ± 
11.7 48.6 ± 13.7** 
Pinprick threshold after hand stimulation (mJ/mm2) 
66.5±27.1 90.7± 41.8** 
Warm threshold after foot stimulation (mJ/mm2) 54.4 ± 10.8 
71 ± 14.6** 
Pinprick threshold after foot stimulation (mJ/mm2) 
83.6±30.8 104.8± 44.3** 
NCS data 
Ulnar SNAP amplitude (μV) 4.4 ± 4.0 3. 9 ± 4.3 
Ulnar SNCV (m/s) 48.1 ± 5.9 47.8 ± 4.6 
Sural SNAP amplitude (μV) 3.6 ± 2.8 4.4 ± 5.3 
Sural SNCV (m/s) 46.9 ± 3.5 47.3 ± 3.4 
LEP data 
Latency of hand N1 (ms) 173.8 ± 14.9 179.9 ± 9.2 
Amplitude of hand N1 (μV) 3.3 ± 2.9 1.5 ± 2** 
Latency of hand N2 (ms) 222.2 2 ± 24.9 228.1 ± 21.3 
Amplitude of hand N2–P2 (μV) 14.8 ± 13.3 6.5 ± 8.1** 
Latency of foot N1 (ms) 206.1 ± 14.9 207.6 ± 24.8 
Amplitude of foot N1 (μV) 2 ± 2.2 0.5 ± 1.2** 
Latency of foot N2 (ms) 261.6 ± 26.4 276.8 ± 43.4 
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Amplitude of foot N2–P2 (μV) 12.4 ± 10.7 2.6 ± 5.4** 
NCS, nerve conduction study; SNAP, sensory nerve action 
potential; SNCV, sensory nerve conduction velocity; LEP, 
laser-evoked potentials. 
IENF density (nerve fibres/mm) 
Thigh 5.8± 3 
Ankle 3± 2.3 
* P < 0.01. 
** P < 0.0001. 
 
Table 1. Clinical and neurophysiological data in patients with 
painful and non-painful neuropathy. 
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Comparisons between neurophysiological data in patients 
with the two more frequent and severe types of pain, 
namely ongoing and provoked pains, showed that the 
mean foot-LEP amplitude in patients with ongoing pain 
was lower than that in patients that have also provoked 
pain (7.4 vs 0.5 μV; P < 0.0001) (Fig.1 and 3). While the 
intensity of ongoing burning pain correlated inversely with 
the foot-LEP amplitude (R = -0.4113; P = 0.0005,   
spearman’s R correlation coefficient), the intensity of 
provoked pain did not (P > 0.2) (Fig. 3). Neither sural-
SNAP amplitude nor foot-LEP amplitude correlated  with 
the intensity of abnormal sensations (P > 0.2); sural nerve 
conduction velocity approached statistical significance (R = 
-0.2459; P = 0.09). The frequency of NCS and LEP 
abnormalities was similar in the various aetiologies (P > 
0.5, χ2-test).  
 
4. Discussion 
In this prospective clinical and neurophysiological study in 
a large cohort of patients with distal symmetric 
142 
 
polyneuropathy, we found that the development of pain 
depends not on age but on the duration of disease. We also 
provide neurophysiological evidence that non-nociceptive 
Aβ-fibre injury has no role in the development of 
neuropathic pain. Among  the various pain qualities we 
studied, the most frequent, ongoing and provoked pains 
arise through different pathophysiological mechanisms. 
The correlation between ongoing burning pain with LEP 
suppression indicates that this type of pain is associated 
with axonal damage whereas the partially preserved LEPs 
in patients with provoked pain suggests that provoked 
pain is related to sensitized nociceptive nerve terminals. 
Our findings in patients with pain related to distal 
symmetric polyneuropathy may open the way to improved 
therapeutic strategies based no longer on aetiology but on 
the underlying pathophysiological mechanisms. 
 
 
4.1. Clinical findings 
When we assessed the various clinical qualities of 
neuropathic pain in distal symmetric polyneuropathy 
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according to the NPSI, we found that burning pain was the 
most frequent (96% of patients) and severe (mean rating 
6.9) type of pain, followed by provoked pains 
(hyperalgesia-allodynia). No other pain types were 
frequent enough to allow us to test any reliable correlation 
with neurophysiological measures. Our finding that age 
did not differ between patients with and without pain 
seems to contrast with previous studies showing that the 
incidence of neuropathic pain conditions peaks in the 
elderly [11]. These reported data probably merely reflect 
the higher frequency of peripheral nerve diseases in the 
elderly, rather than an age-related development of 
neuropathic pain (e.g. the prevalence of peripheral 
neuropathy rises from 2.4% in the general population to 
8% in subjects older than 55 years) [23]. The lack of a 
significant association between pain and age suggests that 
the age-related changes in the somatosensory system, 
reported in many clinical studies [16], have no influence on 
the development of pain in distal symmetric peripheral 
neuropathy. 
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Patients (%) Intensity 0–10 points (mean ± SD) 
Burning pain 96 6.9 ± 2.0 
Pressing pain 38 4.6 ± 1.0 
Paroxysmal pain 26 6.0 ± 2.0 
Provoked pain 44 5.8 ± 3.8  
Abnormal sensations 59 4.5 ± 1.9 
Table 2. NPSI data. 
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Fig. 1A. Neurophysiological assessment in patients with painful 
and non-painful neuropathy. Neural signals recorded in patients 
with painful and non-painful neuropathy (black lines) are 
superimposed to neural signals recorded in a representative 
normal subject (blue lines). While nerve conduction study data 
were similar in the two patients, the patient with pain had 
Abnormal LEPs. NCS: nerve conduction study. SNAP: sensory 
nerve action potential. LEP: laser-evoked potentials. 
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Fig 1B.  A and B skin biopsies images (X40) (from thigh and 
ankle respectively)showing  severe abnormalities in patient with 
distal symmetric neuropathy- complete loss of IENF and 
subepidermal plexus-, compared to control (C,D). Green arrows 
show single nerve fibers arising from subepidermal neural 
plexus bundles (blue arrowshead) and penetrate the basement 
membrane, losing their Schwann cell sheath; then, as naked 
axons, they cross th entire epidermis reaching the stratum 
corneum with an even distribution in hairy skin, and cluster at 
the apex of dermal papillae in glabrous skin (C). Red scale bar = 
70 μm. 
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A previously unreported finding was that in patients with 
pain delay since symptom onset is longer than in those 
without pain. Because our patients’ pain was associated 
with nociceptive pathway damage, we suggest that in 
distal symmetric polyneuropathy the damage to 
nociceptive pathways usually follows non-nociceptive Aβ-
fibre injury. Hence the longer the disease lasts the greater 
the likelihood of nociceptive fibre damage developing and 
provoking neuropathic pain. 
 
 
4.2. Role of Aβ fibres  
NCS studies disclosed no differences between patients 
with and without pain. Nor did NCS data correlate with 
pain intensity. These findings exclude the possibility that 
Aβ-fibre damage plays any noteworthy role in pain 
associated with distal symmetric peripheral neuropathy. 
The previously proposed theory that Aβ fibre loss 
disinhibits nociceptive pathways thus provoking pain 
[2,9,14] originates from the ‘‘gate control theory” and is 
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indirectly supported by evidence that high-frequency low-
intensity  electrical stimulation applied to peripheral 
nerves or spinal cord attenuate pain [8]. 
Because the Aβ fibre damage in our patients was unrelated 
to the development of pain (at least of ongoing and 
provoked pains), we propose that although the input from 
Aβ fibres modulates pain transmission in the central 
nervous system, Aβ fibre loss does not per se provoke 
pain. 
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Fig. 3 Statistical analysis in patients with burning pain, the 
most frequent quality of ongoing  pain and Sural nerve 
amplitude (A), LEP amplitude (B) and IENF density (C): 
only foot LEP amplitude significantly correlated with the 
severity of ongoing pain (R = -0.4113; P = 0.0005). Foot LEP 
amplitude was bigger in patients who complained also 
provoked pain (D). 
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Fig. 3 Symptom onset was longer in pts with pain than in those 
without (3.8 ± 3.1 y vs 2.3 ± 1.7; p=0.01). 
 
 
4.3. Ongoing pain 
When we investigated the pathophysiological mechanisms 
underlying the various qualities of neuropathic pain by 
comparing LEP data in patients distinguished by the NPSI 
we found far smaller amplitudes in patients with ongoing 
pain than in those without pain and the correlation 
between LEP attenuation and pain intensity Intensity was 
highly significant. Whereas the intensity of burning pain, 
the most frequent quality of ongoing pain, correlated 
inversely with the foot-LEP amplitude, it did not with the 
sural sensory nerve action potential nor with IENF. This 
neurophysiological finding shows that ongoing pain in 
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distal symmetric polyneuropathy is related to the damage 
of nociceptive axons. In their study on central pain, Garcia-
Larrea et al. [15] found that ongoing pain was associated 
with markedly reduced amplitude LEPs. Whereas ongoing 
pain in patients with central pain presumably depends on 
a classic deafferentation mechanism, this explanation 
cannot hold true for ongoing pain in distal symmetric 
peripheral neuropathy. In length-dependent neuropathy, 
the short distance between dorsal root ganglion cells and 
dorsal horn prevents an anatomical deafferentation of the 
second-order neurons. We conjecture that the development 
of ongoing pain involves other pathophysiological 
mechanisms. Microneurographic studies in humans 
reported that in patients with peripheral neuropathies 
burning pain is associated with spontaneous, anomalous 
discharges in afferent fibres [4,25].  Skin biopsy studies 
describe reduced intraepidermal nociceptive terminals in 
patients with ongoing pain related to peripheral 
neuropathy [27,34]. In agreement with skin biopsy studies, 
we found that patients with ongoing pain had severely 
reduced amplitude LEPs (laser stimuli activate the 
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intraepidermal nociceptive terminals, rather than the nerve 
axons). We therefore hypothesize that ongoing pain 
reflects the abnormal, spontaneous activity originating in 
damaged nociceptive fibre axons that have lost their 
intraepidermal terminals. Two previous studies by our 
group showed that in patients with postherpetic neuralgia 
and carpal tunnel syndrome, ongoing pain correlated with 
LEP abnormalities and paroxysmal pain correlated with 
Aβ-fibre damage [32,33]. Our present findings on ongoing 
pain in patients with distal symmetric polyneuropathy 
agree with these two previous studies; in this study we 
could not reliably assess a possible correlation between 
paroxysmal pain and A-beta fibre damage, as assessed 
with NCS, because only a few patients with distal 
symmetric polyneuropathy had paroxysmal pain.  
 
4.4. Provoked pain 
Although we found reduced amplitude LEPs also in 
patients with provoked pain, the LEP attenuation was 
significantly lower than that in patients with ongoing pain. 
This difference replicates in peripheral neuropathy the 
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findings by Garcia-Larrea et al. [15] in patients with central 
pain. The partially preserved LEPs in patients with 
provoked pain suggest that provoked pain reflects 
peripheral sensitisation. Over the past decades, ample 
evidence underlines a possible role for sensitised 
nociceptive terminals as primary determinants of pain in 
humans. Previous studies directly demonstrated 
abnormally reduced C nociceptor thresholds to mechanical 
stimuli in patients with provoked pain [6,25]. Whether 
central sensitisation also participates in the development of 
provoked pain remains open to question. In patients with 
peripheral neuropathy the spontaneous firing of 
nociceptive fibres, demonstrated by microneurographic 
recordings [4], may sensitise central nociceptive neurons to 
mechanically evoked input [28]. In patients with chronic 
neuropathic pain, differential nerve blocks showed that 
provoked pain was abolished concurrently with loss of 
tactile sensations at a time when unmyelinated fibres were 
still unaffected [21]. Our neurophysiological findings 
suggest, though do not prove, that provoked pain arises 
through still intact, and sensitised nociceptive nerve 
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terminals. According to our hypothesis in distal symmetric 
polyneuropathy,provoked pain is due to an abnormal 
lowered mechanical threshold of intraepidermal nerve 
terminals and conversely ongoing pain is related to the 
spontaneous activity in damaged nociceptive axons that 
have lost their intraepidermal terminals. All patients with 
pain were taking medications. Although these medications 
reduced pain intensity of about 50% in most of them, no 
drug completely abolished any of the different types of 
pain complained by patients. Thus we believe that our data 
are not significantly influenced by treatment. 
 
4.5. Aetiology-independency 
Pain onset was not influenced by the aetiology. Whereas 
delay since symptom onset was longer in patients with 
pain than in those without, no difference was found 
between the two groups in age  (Fig. 3). This observation, 
together the neurophysiological evidence of damage of 
nociceptive pathway in patients with neuropathic pain, 
leads to conclude that in distal symmetric polyneuropathy 
the injury of nociceptive fibre follows the injury of non-
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nociceptive fibres. So distal symmetric polyneuropathy 
could be complicated by neuropathic pain as much as its 
duration. Loss of IENF does not reflect the presence of 
neuropathic pain: unmyelinated fibre function is available 
even if IENF are decreased, and viceversa it could be 
damaged even if they are visible. Loss of intraepidermal 
fibres is a biomarker of neuropathy. 
In this large cohort of patients with distal symmetric 
peripheral neuropathy with and without pain, we found 
no differences in pain frequencies, pain type, and LEP or 
NCS abnormalities according to aetiology. Conversely, 
regardless of the aetiology, our clinical and LEP studies 
identified two main ‘‘pain phenotypes” [3]: patients with 
ongoing pain and LEP suppression and patients who also 
complain of provoked pains, with a less severe LEP 
attenuation. This difference strongly suggests that different 
types of pain arise through distinct mechanisms regardless 
of aetiology, thus calling for a change in the way we 
classify and treat patients with neuropathic pain in clinical 
practice. As recent European guidelines [1] recommend, 
we agree that instead of grouping patients by aetiology, 
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they should be grouped according to the various qualities 
of pain. This approach might minimize pathophysiological 
heterogeneity within the groups under study and increase 
the power to detect a positive treatment result. 
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Chapter 7: In patients with distal symmetric 
polyneuropathy allodynia is mediated by sensitization of 
peripheral nociceptors  
  
 
Introduction 
In patients with peripheral neuropathy neuropathic pain 
manifests with spontaneous and provoked symptoms (Fig. 
1). Spontaneous symptoms include ongoing pain and 
paroxysmal pain, while provoked pain frequently consists 
of mechanical dynamic allodynia, i.e. pain in response to a 
normally non-painful brushing. The reference standard test 
for diagnosing peripheral neuropathy is the nerve 
conduction study (NCS). NCS nevertheless has the 
disadvantage of assessing non-nociceptive, large-
myelinated fibres (Aβ fibres) alone and provides no 
information on nociceptive pathway function. Current 
neurophysiological assessment of nociceptive pathways 
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relies on recording laser evoked potentials (LEPs). Laser-
generated radiant heat pulses selectively activate Aδ and C 
mechano-thermal nociceptors, and evoke scalp potentials 
related to small myelinated (Aδ) fibres. LEPs are the most 
reliable and agreed neurophysiological method for 
investigating nociceptive fibre function in patients with 
pain [1,2].   
Although allodynia is a frequent complaint in patients 
with peripheral neuropathy, its underlying mechanisms is 
still debated. Most authors consider allodynia to be 
generated at the central level [3]. In patients with 
peripheral neuropathy the spontaneous firing of damaged 
nociceptive afferents may evoke ongoing pain and as a 
secondary effect sensitize second-order nociceptive 
neurons to Aβ-fibre input, thus inducing allodynia [3,4]. 
However some observations suggested that provoked 
pains, including allodynia, may be due to an abnormal 
reduction of the mechanical threshold in sensitized 
nociceptors. 
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Fig.1 In patients with peripheral neuropathy neuropathic pain 
manifests with spontaneous and provoked symptoms. 
Spontaneous symptoms include ongoing pain and paroxysmal 
pain, while provoked pain frequently consists of mechanical 
dynamic allodynia, i.e. pain in response to a normally non-
painful brushing. 
 
More information on the pathophysiological mechanisms 
underlying allodynia related to distal symmetric 
polyneuropathy could be used to develop more effective 
therapeutic approaches for this type of pain. In this 
prospective clinical and neurophysiological study in 
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patients with distal symmetric polyneuropathy we 
investigated the role of non-nociceptive A and 
nociceptive A afferent fibres on the development of 
mechanical dynamic allodynia. To do so we investigated 
A-fibre function with standard nerve conduction study 
(NCS) and nociceptive A-fibre function with laser evoked 
potentials (LEPs). 
 
Methods 
We prospectively collected 200 patients with distal 
symmetric polyneuropathy (114 with pain and 86 without). 
The diagnosis was based on clinical, biological, and 
electrodiagnostic findings, adhering to the criteria 
proposed by England et al. (i.e. patients with symmetrical 
reduction or absence of ankle reflexes, decreased distal 
sensation, and abnormal NCS or skin biopsy). We included 
patients with four different aetiologies: diabetes-related 
neuropathy (70), chemotherapy-induced neuropathy (53), 
cryoglobulinemia related neuropathy (30), neuropathy of 
unknown origin (47). Exclusion criteria were sensory 
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disturbances due to neurological diseases other than distal 
symmetric polyneuropathy and cognitive impairment. To 
limit the heterogeneity of aetiologies we also excluded 
patients with different kinds of neuropathy, when less than 
10 patients was collected. Two staff members examined the 
patients clinically and others did neurophysiological 
testing, with those recording NCS being blinded to LEP 
data and vice-versa. The research was approved by the 
local Ethical Committee. All patients underwent clinical 
examination using bedside tools. Patients were grouped 
according to the clinically documented presence or absence 
of neuropathic pain, as assessed by the DN4 questionnaire. 
The DN4 questionnaire is clinician-administered screening 
tool that comprises various clinical items including 
allodynia and indicates neuropathic pain when the score is 
≥4. Patients with neuropathic pain were further divided in 
two groups: with and without allodynia, as assessed by the 
dedicated items of the DN4 (all patients without allodynia 
suffered from ongoing pain). Patients also underwent 
motor and sensory NCS using surface recording electrodes 
with standard placement. Methods used adhered to those 
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recommended by experts of the International Federation of 
Clinical Neurophysiology [18]. NCS comprised sensory 
nerve action potentials (SNAP) and conduction velocities 
recorded from sural, ulnar and superficial radial nerves. 
Other nerve function variables examined were compound 
motor action potential (CMAP) amplitude and peroneal, 
tibial and ulnar nerve condition velocities. We studied 
LEPs using a neodymium:yttrium-aluminium-perovskite 
(Nd:YAP) laser. The dorsum of the right foot and the left 
hand were stimulated by laser pulses at relatively high 
intensity (150–200 mJ/mm2), short duration (5 ms), and 
small diameter (~5 mm) eliciting pinprick sensations. 
Subjects lay on a couch and wore protective goggles. To 
determine the laser perceptive threshold we delivered a 
series of stimuli at increasing and decreasing intensity, and 
defined the perceptive threshold as the lowest intensity at 
which the subjects perceived at least 50% of laser stimuli. 
The early, lateralized component, N1, and the main 
complex, N2-P2, were recorded through disc electrodes 
from the temporal areas (Tc) referenced to frontal area (Fz) 
and vertex (Cz) referenced to the nose. From 10 to 20 trials 
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devoid of artefacts were collected and averaged offline. We 
measured peak latency and amplitude (peak-to-peak) of 
the temporal N1 component and the N2-P2 vertex 
complex. NCS and LEP data were compared with 
normative ranges established in our laboratory. 
 
Statistical analysis  
Mann-Whitney U-test was used to analyse the differences 
in neurophysiological data between patients with and 
without pain according to the DN4, and (within the group 
of patients with pain) neurophysiological differences 
between those with and without allodynia. The differences 
of frequency of neuropathic pain and allodynia across the 
different aetiologies were analysed with the Chi-square test 
and those of neurophysiological data with the Kruskal-
Wallis test. P values of < 0.05 were considered significant. 
All results are reported as mean ± SD. 
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Results 
Of the 200 selected patients, all having distal, symmetric 
sensory disturbances most had a predominantly sensory 
neuropathy, 114 with pain and 86 without. Although 
clinical assessment showed that most patients, regardless 
of pain, had sensory deficits involving all sensory 
modalities, pinprick and thermal thresholds assessed with 
laser stimuli were significantly higher in patients with pain 
than in those without (P < 0.001, Mann-Whitney test). In 
the group of patients with pain DN4 identified 44 patients 
with allodynia, 70 without. Chi square test showed no 
differences in frequency of pain and allodynia across the 
different aetiologies (P > 0.5). Kruskal-Wallis test showed 
no differences in neurophysiological data across the 
different aetiologies (P > 0.5). Whereas LEP amplitude 
(both the N1 component and the N2-P2 complex) was 
significantly lower in patients with pain than in those 
without (P < 0.0001, Mann-Whitney test), NCS data did not 
differ (P > 0.2); nor did LEP latency and sensory 
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conduction velocities differ in the two groups (P > 0.2). 
Comparisons between neurophysiological data in patients 
with allodynia showed that while the mean foot-LEP 
amplitude was higher in patients with allodynia than in 
those with ongoing pain only, (P = 0.006), NCS data 
(including the sural SNAP amplitude) did not differ (P > 
0.2).  
 
Discussion  
In this prospective clinical and neurophysiological study in 
a large cohort of patients with distal symmetric 
polyneuropathy we found that neuropathic pain is 
associated with a damage of nociceptive pathway as 
assessed by LEP recordings. Furthermore the partially 
preserved LEPs in patients with allodynia suggests that 
this type of pain is related to partially preserved and 
sensitised nociceptive nerve terminals. In this study we 
investigated a large cohort of patients with distal 
symmetric polyneuropathy due to different causes. When 
we investigated neurophysiological differences between 
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patients with and without allodynia we did not distinguish 
across the specific aetiology, because previous studies 
showed that neuropathic pain does not depend on the 
aetiology [5]. Also in this study we found no differences in 
pain frequencies, LEP or NCS abnormalities according to 
aetiology. Hence we believe that to seek information on 
pain mechanisms patients should not be grouped by 
aetiology. In our cohort of patients with distal symmetric 
polyneuropathy we also included patients with 
cryoglobulin-related neuropathy. Although in this 
condition nerve damage is due to the vasculitis, and thus 
multiple mononeuropathy should be expected, all our 
patients presented with distal symmetric sensory 
disturbances. This feature is probably due to the low 
temperature at which cryoglobulins precipitate. The 
extremity temperature is usually lower that the rest of the 
body, thus increasing the possibility of cryoglobulin 
precipitation causing vascular occlusion and nerve 
damage.   All patients with pain were taking medications. 
Although these medications reduced pain intensity of 
about 50% in many of them, no drug completely abolished 
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any of the different types of pain complained by patients. 
Thus we believe that our data are not significantly 
influenced by treatment. We found that while the 
amplitude of LEPs was significantly smaller in patients 
with pain, NCS data  did not differ. These findings support 
the current knowledge on neuropathic pain. Previous 
clinical, neurophysiological, and neuropathological 
investigations showed that in patients with peripheral 
neuropathy of various aetiologies neuropathic pain is 
invariably associated with nociceptive pathway damage 
and unrelated to Aβ-fibre damage [5]. We may 
hypothesize that in patients with distal symmetric 
polyneuropathy pain arises from damaged and 
dysfunctioning nociceptive fibres.  Comparisons between 
neurophysiological data in patients with and without 
allodynia showed that NCS data did not differ. This 
finding argue against the possible role of Aβ-fibres. 
Whether allodynia were mediated by Aβ-fibres, a partial, 
though statistically significant, preservation of this type of 
afferent fibres should be detected in a large sample of 
patients. The lack of any differences in Aβ-fibre mediated 
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NCS between patients with and without allodynia suggest 
that this set of fibre is dissociated from allodynia.  
Although we found a reduced amplitude of LEPs also in 
patients with allodynia the LEP attenuation was 
significantly lower than that in patients without this type 
of pain. This finding indicates that patients with allodynia 
have partially spared nociceptive afferents, and suggests 
that allodynia might be mediated by peripheral 
sensitization of nociceptors, manifesting with an abnormal  
lowered mechanical threshold of intraepidermal nerve 
terminals. Over the past decades, ample evidence 
underline a possible role for sensitised nociceptive 
terminals as primary determinants of pain in humans. 
Previous studies directly demonstrated abnormally 
reduced C nociceptor thresholds to mechanical stimuli in 
patients with provoked pain [6]. In patients with 
postherpetic neuralgia many studies showed that allodynia 
correlates with the sparing of thermal sensation [7], thus 
suggesting the need of a relative sparing of thermal-pain 
afferent fibres. Support for the peripheral sensitization as 
the main mechanism for allodynia comes also from 
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placebo-controlled trials showing that topical application 
of lidocaine and capsaicin provides significant pain relief 
[8]. Admidettly our data cannot exclude the possibility that 
central sensitization participates in the development of 
allodynia, but strongly suggest that it is unnecessary. Our 
study showing that allodynia is associated with partially 
preserved nociceptive afferent fibres and unrelated to Aβ-
fibres could be useful in designing new treatment 
strategies targeted to this type of pain. 
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Chapter 8: Clinical, neurophysiological and skin biopsy 
study of peripheral neuropathy related to 
cryoglobulinaemia 
 
 
Introduction 
 
In addition to Meltzer's triad of purpura, weakness and 
arthralgias, the neurological system could be  involved in a 
significant proportion of patients affected by 
cryoglobulinemia in different ways, as peripheral 
neuropathy, cranial nerve involvement and vasculitic 
central nervous system involvement [1] (Table 1 and 2). 
The neurological complications are predominantly in the 
peripheral nervous system  and are mainly associated with 
mixed cryoglobulinaemia [1]. Peripheral neuropathy range 
from pure sensory axonopathy to mononeuritis multiplex 
[2]. The most frequently described form is a distal sensory 
or sensory-motor peripheral neuropathy [3]. Prevalence of 
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peripheral neuropathy varied widely.  In a prospective 
study of 321 patients with chronic HCV infection, 50% of 
whom were cryoglobulin positive, clinically symptomatic 
sensory or motor peripheral neuropathy was found in 9% 
[4]. In a study of 26 HCV-mixed cryoglobulinaemia 
patients [5], neurologic examination revealed a neuropathy 
in 48% of subjects, while electrophysiologic variables were 
altered in 82%. The tempo of the vasculitic neuropathy may 
be subacute, chronic, or acute on chronic [6]. The 
exacerbation of  neuropathy occurs simultaneously with 
the failure of other organs, as a result of the increased 
activity of the underlying vasculitis. In patients with distal 
polyneuropathy, nerve conduction studies are in keeping 
with a predominantly axonal process, mainly affecting the 
sensory nerves. Neuropathological data show axonal 
degeneration, differential fascicular loss of axons, signs of 
demyelinization and small-vessel vasculitis, with 
mononuclear cell infiltrates in the perivascular area (Fig. 
1a) [7].  
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Table 1. Salient Clinical features of the crioglobulinemia 
syndromes: cryoglobulinaemic vasculitis (CV) is a systemic 
vasculitis associated with serum positive cryoglobulins that is, 
immune complexes composed of rheumatoid factor (RF) 
monoclonal or polyclonal against polyclonal IgG (type II or type 
III cryoglobulins, respectively) or immunoglobulins without RF 
activity (type I), which reversibly precipitate or form a gel at a 
temperature below 37°C. Type I and II CV are usually linked to 
non- malignant B-cell lymphoproliferation, type III often 
triggered by chronic hepatitis C virus  infection. 
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Table 2. Laboratory features of the crioglobulinemia   
syndromes 
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Fig. 1. Transversal section of superficial peroneal nerve biopsy 
from patients with hepatitis C virus-associated mixed 
cryoglobulinaemia peripheral neuropathy. (a) Perivascular 
inflammatory mononuclear cell infiltrates. Mononuclear cells did 
not invade the blood vessel wall (-25). (b) Necrotizing arteritis 
with perivascular and transluminal inflammatory cell infiltration 
and concurrent wall fibrinoid necrosis (-400). Images from Rev 
Neurol (Paris) 2002; 158:920–924. 
 
 
Polyneuropathy usually presents with painful, asymmetric 
paresthesias that later become symmetric [8]. The pain is 
positively associated with the presence of vasculitis [8].  
We designed this clinical, neurophysiological and 
histopathological study in patients with distal symmetric 
neuropathy  related to cryoglobulinemia in attempt to 
make correlations between  clinical features, such age and 
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duration of disease, and to investigate the role of primary 
afferent neurones (non-nociceptive Aβ and nociceptive Aδ 
and C afferent fibers) on the development of  neuropathic 
pain. We assessed clinical variables including the various 
qualities of neuropathic pain with the NPSI, Aβ -fibers 
function with nerve conduction study (NCS), Aδ function 
with laser evoked potentials (LEPs) and  C-fibers  with skin 
biopsy and IENF density. 
 
2.Methods 
We prospectively collected 48 patients with 
cryoglobulinemia. The diagnosis was based on clinical, 
pathologic  and serologic   findings, adhering to the criteria 
proposed by Ferri C et al. [9]. All patients underwent 
clinical examination, nerve conduction study, LEP 
recordings and skin biopsy. One staff member examined 
the patients clinically and  administered the NPSI 
questionnaire ; others did neurophysiological testing and 
skin biopsy, with all the members being blinded each other 
. We collected 30 patients with peripheral neuropathy: 23 
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with neuropathic pain and 7 without. The diagnosis of 
distal symmetric polyneuropathy was based on clinical, 
biological, and electrodiagnostic findings, adhering to the 
criteria proposed by England et al. [10]. Patients with 
symmetrical reduction or absence of ankle reflexes, 
decreased distal sensation, and abnormal NCS or LEPs 
were included in this study. Exclusion criteria were 
diagnosis of inflammatory or inherited neuropathies, 
sensory disturbances due to neurological diseases other 
than distal symmetric polyneuropathy cryoglobulinemia 
related, cognitive impairment. The research was approved 
by the local Ethical Committee. 
 
2.1 Clinical examination 
All patients underwent a detailed neurological 
examination using bedside tools. Tactile sensation was 
investigated with a piece of cotton wool, vibration with a 
tuning fork (128 Hz), and pinprick sensation with a 
wooden cocktail stick. In all patients laser stimuli were 
used for a quantitative evaluation of warm and pinprick 
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sensations. Gait impairment, and muscle strength were 
assessed with the Medical Research Council score. Patients 
were also asked to report dysautonomic symptoms. 
Patients were grouped according to the clinically 
documented presence or absence of neuropathic pain rated 
≥4 on the 0–10 numerical rating scale and persisting since 
at least one month [11].  Patients with pain completed the 
NPSI questionnaire. The NPSI subscores were calculated 
for the various types of pain: ongoing pain (burning and 
pressing pain), paroxysmal, provoked pain and abnormal 
sensations (paraesthesias and dysaesthesia). 
 
2.2. Neurophysiological examination and skin biopsy 
Patients underwent motor and sensory NCS using surface 
recording electrodes with standard placement. Methods 
used adhered to those recommended by experts of the 
International Federation of Clinical Neurophysiology [12]. 
NCS comprised sensory nerve action potentials (SNAPs) 
and conduction velocities recorded from sural, ulnar and 
superficial radial nerves. Other nerve function variables 
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examined were compound motor action potential (CMAP) 
amplitude and peroneal, tibial and ulnar nerve conduction 
velocities. To study LEPs, we used a neodymium:yttrium-
aluminium- perovskite (Nd:YAP) laser (wavelength 1.34 
mm, pulse duration 2–20 ms, maximum energy 7 J). The 
dorsum of the right foot and the left hand was stimulated 
by laser pulses at relatively high intensity (150–200 
mJ/mm2), short duration (5 ms), and small diameter (˜5 
mm) eliciting pinprick sensations. The laser beam was 
shifted slightly after each stimulus. The interstimulus 
interval was varied pseudo-randomly (10–15 s). Subjects 
lay on a couch and wore protective goggles. They were 
instructed to keep their eyes open and gaze slightly 
downwards. To determine the laser perceptive threshold, 
we delivered a series of stimuli at increasing and 
decreasing intensities, and defined the perceptive 
threshold as  the lowest intensity at which the subjects 
perceived at least 50% of laser stimuli. The early, 
lateralized component, N1, and the main complex, N2–P2, 
were recorded through disc electrodes from the temporal 
areas (Tc) referenced to frontal area (Fz) and vertex (Cz) 
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referenced to the nose. From 10 to 20 trials devoid of 
artefacts  were collected and averaged offline. We 
measured peak latency and amplitude (peak-to-peak) of 
the temporal N1 component and the N2–P2 vertex 
complex. NCS and LEP data were compared with 
normative ranges established in our laboratory. Patients 
underwent skin biopsies from the proximal region of the 
thigh (20 cm below the anterior iliac spine) and the distal 
region of the leg (10 cm above the lateral malleolus, with 
the sural nerve territory). Biopsies were taken after local 
anesthesia using a 3 mm disposable punch under sterile 
technique. Three sections randomly  chosen from each 
biopsy were immunoassayed with polyclonal anti-protein-
gene- product 9.5 antibodies using the free-floating 
protocol for bright field immunohistochemistry [13,14]. 
The linear density of  intraepidermal fibers was calculated 
following the rules reported by the guidelines of the 
European Federation of the Neurological Societies [15]. 
IENF data were compared with normative ranges 
established in our laboratory. 
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2.3. Statistical analysis 
We used Mann–Whitney U-test to analyze the differences 
in neurophysiological and clinical data between patients 
with and without pain. Chi-square test was used to assess 
the frequency of the various qualities of neuropathic pain. 
We used the nonparametric Spearman’s R correlation 
coefficient to correlate the intensity of ongoing-burning 
pain  and allodynia, the most frequent qualities of pain,  
with foot-LEP amplitude, IENF density. P values of <0.05 
were considered significant. All results are reported as 
means ± SD. 
 
3. Results 
Of the 30 selected patients, all having distal, symmetric 
sensory disturbances mostly had a predominantly sensory 
neuropathy and 23 had pain  as assessed by the DN4 
questionnaire. The NPSI showed that the most frequent 
types of pain were the  ongoing burning pain and 
allodynia. NPSI  analysis showed that nearly all patients 
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had ongoing pain: 14 had burning pain (mean rating 6.5 ± 
2.0). Of the  14 patients with pain 10  had also allodynia  
(mean rating 5.8 ± 3.8). The various kinds of pain differed 
significantly in frequency (P < 0.0001, χ2-test), burning 
pain being more frequent and severe than the other types 
of pain.  Patients with peripheral neuropathy had an older 
age than those without (P=0.03, Mann Whitney test) (Fig. 
2). 
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Figure 2. Patients with peripheral neuropathy had an  
older age than those without (P=0.03, Mann Whitney test) 
191 
 
 
 
 
 
Fig .3 A and B skin biopsies images (X40) (from thigh and ankle 
respectively) in patient with distal symmetric neuropathy 
showing  lower IENF and subepidermal plexus than the control 
(C,D). Green arrows show single nerve fibers arising from 
subepidermal neural plexus bundles (green arrowshead). Red 
scale bar = 70 μm. 
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Painful  
Neuropathy (23) 
Non-painful 
Neuropathy (7) 
 
Clinical data    
Age (year) 
 
65.4±8.9                        57.7 ± 13 
 
 
NCS data    
Sural SNAP  (µV) 
 
2.6±5 3.5±8.8  
 
Ulnar SNAP (µV) 7±38 10±5.4  
LEP data    
N1 hand (µV) 0.78±2.5 1.96±2.6*  
N1 hand (ms) 243±72 209±27  
N2-P2 hand (µV) 3.1 ±7.5 16.4±12*  
N2-P2 hand (ms) 
N1 foot (µV)  
N1foot (ms) 
264.5±28 
3±7 
186±21 
247±31 
3.1±3.4* 
163±20 
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N2-P2 foot (µV) 
N2-P2 foot (ms) 
IENF (f/mm) 
THIGH                     
ANKLE                     
11±11.1 
320±35 
 
5.7±3                                                                                        
2.9±1.75 
28±8.9* 
211±30 
 
6.5±2.8 
3.2±1.75 
 
 
Table 3. Clinical, neurophysiological and morphological data in 
pts with painful and non-painful neuropathy. NCS, nerve 
conduction study; SNAP, sensory nerve action; LEP, laser 
evoked potential; IENF, intraepidermal fibers. *P<0.0001 
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Whereas LEP amplitude (both the N1 component and the 
N2–P2 complex) significantly differed between patients 
with and without pain (P < 0.0001), NCS and IENF density 
data did not (P =0.6). as assessed by skin biopsy (Fig. 3) 
(Table 3).  
 
4. Discussion 
In this prospective (although evaluated at one time point 
only, the patients were sequentially examined and 
recruited) clinical and neurophysiological study in a cohort 
of patients with cryoglobulinemia, we collected all patients 
with  distal symmetric sensory neuropathy. Although in 
cryoglobulinemia nerve damage is due to the vasculitis, 
and thus multiple mononeuropathy should be expected, 
no-one presented mononeuropathy. This feature is 
probably due to the low temperature at which 
cryoglobulins precipitate. The extremity temperature is 
usually lower that the rest of the body, thus increasing the 
possibility of cryoglobulin precipitation causing vascular 
occlusion and nerve damage.  Moreover, our patients 
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predominantly showed sensory polyneuropathy. The 
possible mechanism may be in the pathogenesis of 
neuropathy vasculitis-related: the small vessels of the 
sensory nerves fascicles are more sensitive than those of 
motor fascicles [16].   
We found that whereas LEP amplitude significantly 
differed between patients with and without pain, NCS data 
did not.  We provide neurophysiological evidence that 
non-nociceptive Aβ-fibre injury has no role in the 
development of neuropathic pain. Moreover, the 
correlation between ongoing burning pain with LEP 
suppression indicates that this type of pain is associated 
with axonal damage of nociceptive fibers, as assessed 
previously [17]. Although IENF density technique assesses 
nociceptive fibers as LEPs recordings, we found that only 
LEPs data have correlations with the severity of 
neuropathic pain. This could be explained by the fact that 
skin biopsy selectively shows ENFs arising from 
subepidermal neural plexus bundles and penetrating the 
basement membrane, losing their Schwann cell sheath. 
Whereas laser  radiant-heat pulses excite the free nerve 
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endings  both Aδ and C in the superficial skin layers. In 
clinical practice, their main limitation is that ultralate LEPs 
(related to C-fibre activation) are technically more difficult 
to record. They are usually recorded after  laser stimuli 
(biggers diameter and longer duration than Aδ stimuli 
setting) applied in trigeminal regions, where the density of 
full C fiber is higher and the  distancy  from the central 
nervous system is lower than any other region in the body . 
It is much more difficult their recording after stimuli 
applied in extra-trigeminal areas. Intraepidermal density 
involves just  nerve fibers crossing the derma-epidermal 
junction, but this allows to obtain important informations 
about unmyelinated fibers of extra-trigeminal areas.  We 
observed that the density of intraepidermal fibres 
correlated with the duration of the disease: the longer  
cryoglobulinemia lasts a worse intraepidermal 
innervations , as assessed by skin biopsy.   Our finding 
agree to previous studies showing that the incidence of 
neuropathic pain conditions peaks in the elderly [18]. 
These reported data probably merely reflect the higher 
frequency of peripheral nerve diseases in the elderly (e.g. 
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the prevalence of peripheral neuropathy rises from 2.4% in 
the general population to 8% in subjects older than 55 
years) [19]. The age-related changes in the somatosensory 
system, reported in many clinical studies [20], have 
influence on the development of pain in distal symmetric 
peripheral neuropathy. 
 In conclusion our findings  indicate that neuropathic pain 
reflects damage to nociceptive axons, as showed by the 
correlation between the intensity of ongoing pain and LEP 
attenuation;  moreover loss of nociceptive axons is a 
biomarker of the duration and the severity of neuropathy 
as assessed by skin biopsy. 
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Chapter 9: Hyperalgesic activity of kisspeptin in mice. 
 
Chapter based on: Hyperalgesic activity of kisspeptin in mice. 
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Trabucco A, Biasiotta A, Biagioni F,  Cruccu G, Copani A, Colledge 
WH,  Sortino MA, Nicoletti F, Chiechio S 
 
Background 
Kisspeptin is a 54-amino acid peptide originally discovered 
for its activity as metastasis-suppressor [1]. It is encoded by 
the Kiss1 gene as a 145-amino acid precursor protein and 
cleaved to a 54- amino acid protein as well as into shorter 
products (kisspeptin-10,-13,-14) known to play a critical 
role in the neuroendocrine regulation of reproduction [2-5]. 
In the brain, kisspeptin is localized not only in areas 
involved in gonadotropin secretion, but also in other 
regions such as the amygdala, hippocampus, and the 
periacqueductal gray [6,7]. Its action is mediated by a 7-TM 
receptor named GPR54, also known as KISS1R, which is 
coupled to polyphosphoinositide hydrolysis via a Gq/11 
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GTP binding protein [2, 8]. Loss-of-function mutations of 
GPR54 cause a non-Kallman variant of   
hypogonadotropic/hypogonadism in humans (i.e. 
hypogonadotropic/hypogonadism without anosmia) [2, 9]. 
Interestingly, the expression of kisspeptin and GPR54 is 
not restricted to the hypothalamus. Relatively high levels 
of kisspeptin and GPR54 are found in forebrain regions, 
such as the hippocampus and amygdala, as well as in the 
periacqueductal grey [10]. The investigation of the 
extrahypothalamic functions of kisspeptin is still at its 
infancy. Treatment with kainic acid increases kisspeptin 
mRNA levels in the hippocampus, and kisspeptin 
enhances the amplitude of excitatory postsynaptic currents 
in granule cells of the hippocampal dentate gyrus [6, 7]. 
This suggests a potential role for kisspeptin in the 
regulation of synaptic plasticity in the CNS. Recent 
findings have shown an intense kisspeptin and GPR54 
immunostaining in dorsal root ganglia (DRG) neurons and 
in lamina I and II of the dorsal horns of the spinal cord [11, 
12]. The transcripts of kisspeptin and GPR54 are up-
regulated in DRG and dorsal horn neurons in the complete 
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Freund adjuvant (CFA) model of chronic inflammatory 
pain [12], suggesting that kisspeptin may play a role in 
mechanisms of nociceptive sensitization. However, how 
precisely kisspeptin regulates pain sensitivity is obscure at 
present. We now report that peripheral or intrathecal 
injection of kisspeptin causes hyperalgesia and induces 
biochemical changes that are consistent with mechanisms 
of peripheral and central nociceptive sensitization. 
 
Methods 
Animals Adult male CD1 mice (Charles River, Calco, CO, 
Italy), 129S6/Sv/Ev wild-type, and 129S6/Sv/Ev Gpr54- 
knock-out mice [13] aged between 8 and 9 weeks were 
used in these experiments. Mice were housed 10 animals 
per cage with food and water ad libitum in standard 12/12 
h light/dark cycle, for a period of 2 weeks before testing. 
All experiments were carried out according to the 
recommendations of Institutional Animal Care and Use 
Committee (IACUC). All efforts were made to minimize 
animal suffering and to reduce the number of animals 
used. 
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Drug administration Kisspeptin (Calbiochem Merck 
KGaA, Darmstadt, Germany) was dissolved in 5% DMSO 
and injected intrathecally (3 μl) or subcutaneously (5 μl) 
into the plantar surface of the right hind paw using a 10 μl 
luertip-syringe (Hamilton) fitted with a 30-gauge needle. 
p234 (Sigma-Aldrich, St. Louis, MO) was dissolved in 
phosphate buffered saline (PBS) and injected in a volume 
of 3 μl for intrathecal administration or 5 μl for intraplantar 
administration. Behavioral experiments Hot plate test. The 
hot plate test (Ugo Basile, Italy) was used to asses thermal 
sensitivity. CD1 mice were placed onto the hot plate at the 
temperature of 55 ± 0.1 °C. Paw withdrawal thresholds 
were determined in the hind paws of ipsilateral hind limb. 
Animals were kept on the plate until the first sign of 
ipsilateral paw lift or lick was recorded as basal 
withdrawal latency (pre-drug latency). A maximum cut-off 
paw withdrawal latency of 20 seconds was chosen to 
prevent tissue damage (cutoff time). Post-dose thresholds 
were taken at 5, 15, 30, and 60 minutes after drug 
administration (post-drug latency). For each animal, results 
were expressed as the percentage maximum possible effect 
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(%MPE) calculated using the following formula: [(post-
drug latency – pre-drug latency)/(cutoff time – pre-drug 
latency)] x 100.  
Formalin test. Inflammatory pain was assessed using the 
formalin test. Ten μl of a 5% formalin solution was injected 
subcutaneously into the plantar surface of the right hind 
paw of CD1 mice. After the injection, mice were 
immediately placed in a plexiglas box (20 × 15 × 15 cm) 
surrounded by mirrors to allow the observation of 
nociceptive responses that include licking, lifting and 
shaking of the injected paw. Tests were performed 
between 08:00 h and 12:00 h to minimize variability. 
Mice were observed for 1 hour. Formalin scores were 
separated into two phases, phase I (0-10 min) and phase II 
(15-45 min). The mean behavioural score was calculated in 
blocks of 5 min for each of the two phases. A mean 
response was then calculated for each phase. 
Spontaneous pain. CD1 mice that received intraplantar 
injection of kisspeptin or vehicle were placed in a cage 
immediately after the injection, and the duration of hind 
paw lifting and licking during the first 5 minutes were 
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measured. All behavioral tests were analyzed by observers 
blind to the treatment of the animals.  
 
 
Immunohistochemistry:  
Skin biopsies. Animals were euthanized with chloral 
hydrate (320 mg/kg i.p.). 2.5-mm punch skin biopsies from 
the plantar surface of the hind paws were performed and 
fixed in Zamboni fixative (2% paraformaldehide, 15% 
picric acid saturated aqueous solution, 0.1 M phosphate 
buffer pH 7.4) for 24 hours. Biopsies were cryoprotected 
with 20% sucrose in PBS overnight at 4ºC. Sections of 10 
μm were cut at the cryostat and mounted on glass slides 
for immunohistochemical analysis. Immunohistochemistry 
procedures were performed as previously described [14].  
Double immunofluorescence was performed in skin 
biopsies from CD1 male mice incubating sections 
overnight with polyclonal rabbit anti-human PGP 9.5 
(1:1000; AbD Serotec, Kidlington, UK) and goat polyclonal 
anti-GPR54 (1:20; Santa Cruz Biotechnology, Santa Cruz, 
CA) and then for 1 h with secondary fluorescein anti-rabbit 
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(1:100; Vector Laboratories, Burlingame, CA) and Cy3 
antigoat (1:400; Chemicon, Billerica, MA) antibodies. 
Control staining was performed without the primary 
antibodies. Immunostaining was performed in skin 
biopsies from male 129S6/Sv/Ev wildtype and 
129S6/Sv/Ev Gpr54- knock-out mice [13] to test the 
specificity of the anti-GPR54 antibody. Tissue sections 
were incubated overnight with goat polyclonal anti-GPR54 
(1:20; Santa Cruz Biotechnology, Santa Cruz, CA) and then 
for 1 h with secondary biotin-coupled anti-goat (1:100; 
Vector Laboratories, Burlingame, CA). SG (SG substrate 
kit; Vector Laboratories, Burlingame, CA, USA) chromogen 
was used for detection. Spinal cord. CD1 mice (n=5 per 
group) were used. 3 min after kisspeptin (3 nmol) or 
vehicle (DMSO) were co-injected with formalin in the right 
hind paw and lumbar spinal cords were removed and 
fixed in formalin (4%) overnight, transferred in 70% 
ethanol and included in paraffin. 
Ten serial sections were cut and used for 
immunohistochemical analysis. Deparaffinized sections 
were treated with 10 mmol/L citrate buffer, pH 6.0, and 
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heated by microwave for 10 minutes for antigen 
unmasking. Sections were soaked in 3% hydrogen 
peroxide to block endogenous peroxidase activity. Tissue 
sections were incubated overnight with monoclonal rabbit 
antibody anti phospho-p44/42 (Erk1/2) (Thr202/Tyr204) 
(D13.14.4E)XPTM (1:200; Cell Signaling Technology, 
Denver, MA, USA) and then for 1 h with secondary biotin-
coupled anti-rabbit (1:200; Vector Laboratories). 3,3-
Diaminobenzidine tetrachloride was used for detection. 
Control staining was performed without the primary 
antibodies. 
Densitometric analysis of p-ERK immunoreactivity Intensity of 
p-ERK immunoreactivity was quantified by measuring the 
optical densities of the outer laminae of the dorsal horn in 
the stained sections relative to the background (ventral 
horn) . Images were acquired using a computer-based 
microdensitometer (NIH Image Software, Bethesda, MD, 
USA). Values were the mean of measurements made on ten 
sections (10 μm) sampled 1 into a 3 series spanning the 
extent of the L4-L5 spinal cord. Western blot analysis CD1 
Mice were sacrificed 3 min following treatment and skin 
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lysates of all groups were processed in western blot. Skin 
homogenates were obtained as previously described [15]. 
Ten μg of total protein were separated by 10% SDS-
polyacrylamide gel electrophoresis and electrophoretically 
transferred onto protein-sensitive nitrocellulose 
membranes (Criterion blotter; Bio-Rad Laboratories, 
Hercules, CA). The membranes were blocked in Odyssey 
blocker (LI-COR Biosciences, Lincoln, NE) for 1 h, and the 
following primary antibodies were used: anti-TRPV1 
(phospho S800) polyclonal antibody (1:400, Abnova, 
Aachen, Germany); anti-actin monoclonal antibody (1:1000, 
Sigma). Secondary antibodies were: goat anti-rabbit 
(IRD800CW) and goat antimouse (Alexa 680, LI-COR, 
Bioscience) antibodies. Proteins were detected with the 
Odyssey Infrared Fluorescence Imaging System (LI-COR). 
 
Results 
Knowing that the kisspeptin receptor, GPR54 (KISS1R), is 
present in DRG neurons [12], we performed 
immunofluorescent analysis to examine whether the 
receptor was also present in peripheral nociceptors. We 
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focused on the peripheral role of kisspeptin in the 
modulation of acute and inflammatory pain. First we 
examined the specificity of the GPR54 antibody in skin 
biopsies from GPR54 KO mice. No immunostaining was 
seen in sensory nerve terminals of GPR54 KO mice (Fig. 1). 
The nature of the nonspecific staining seen in the outer 
portion of the skin of GPR54 KO mice is unknown. In 
punch skin biopsies from the mouse hind paw, sensory 
fibers ascending  vertically between the keratinocytes to 
reach the stratum corneum of the epidermis were 
identified by fluorescent immunostaining for the neuron-
specific ubiquitin hydrolase, PGP9.5 [14] (Fig. 2A). These 
fibers also expressed GPR54, as shown by double 
fluorescence immunostaining (Fig. 2B,C). Behavioral 
experiments were performed after peripheral (intraplantar) 
and central (intrathecal) administration of kisspeptin at 
doses ranging from 0.1 to 3 nmol [16]. We first examined 
the effect of intraplantar injection of kisspeptin on 
nocifensive behavior in naïve mice. Nocifensive behavior 
consisting of licking, flinching and shaking of the injected 
paw was evaluated after a single injection of kisspeptin (3 
212 
 
nmol/5 μl) or vehicle into the plantar surface of the right 
hind paw. The time spent in nocifensive behavior was 
recorded for 5 min after the injection. Intraplantar injection 
of kisspeptin (3 nmol/5 μl) induced brief nocifensive 
behavior that lasted for about 5-15 seconds, whereas no 
signs of pain were seen in vehicle-injected mice (Fig. 3A). 
We then assessed the  effect of kisspeptin on acute thermal 
pain using the hot plate test. Intraplantar injection of 
kisspeptin (3 nmol/5 μl) significantly reduced paw 
withdrawal latency in response to heat as compared to 
intraplantar injection of vehicle (Fig. 3B), whereas no 
differences were observed after p234 injection (0.1 nmol/5 
μl) (Fig. 3C). 
For the assessment of inflammatory pain, mice were 
subjected to the formalin test, 15 min after intraplantar (0.1, 
1 and 3 nmol/5 μl) or intrathecal (0.1, 0.5 and 1 nmol/3 μl) 
injection of kisspeptin. Intraplantar injection of formalin 
elicits a biphasic nocifensive response characterized by 
licking, lifting and shaking of the injected paw. The first 
phase of the formalin test, starting immediately after 
formalin injection and lasting for about 10 min, represents 
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a form of acute pain elicited by direct activation of 
nociceptors. The second phase of the test (occurring 
approximately 15-45 min after formalin injection) reflects 
the development of nociceptive sensitization in the dorsal 
horns of the spinal cord [17, 18]. Intraplantar injection of 
both 1 and 3 nmol/5 μl of kisspeptin (15 min prior to 
formalin injection) caused hyperalgesia in the first and 
second phases of the formalin test whereas no effects were 
observed at the lower dose of 0.1 nmol/5 μl (Fig. 4). We 
also assessed the effect of the selective GPR54 antagonist, 
peptide 234 (p234) [19] in the formalin test. As opposed to 
kisspeptin, intraplantar injection of p234 (1 nmol/5 μl; 15 
min prior to formalin) significantly reduced nocifensive 
behavior (Fig. 4B). A lower dose of p234 (0.1 nmol/5 μl) 
induced a trend to an analgesic effect, which was not 
statistically significant (Fig. 4B). We also examined 
whether intrathecal injection of kisspeptin or p234 could 
affect nocifensive behavior in the formalin test. Kisspeptin 
injected intrathecally at the dose of 1 nmol/3 μl, 10 min 
prior to intraplantar injection of formalin, significantly 
increased nocifensive behavior in the first and second 
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phases of the formalin test. A lower dose of kisspeptin (1 
nmol/3 μl) caused hyperalgesia in the first phase, and a 
non significant trend to hyperalgesia in the second phase 
of the test (Fig. 4C). When injected intrathecally, 
compound p234 was analgesic at doses of 0.1 and 1 nmol/3 
μl in both phases of the formalin test (Fig. 4D). The 
hyperalgesic activity of kisspeptin in both phases of the 
formalin test led us to investigate whether the peptide 
could induce biochemical changes that were consistent 
with mechanisms of peripheral and central sensitization. 
We therefore examined TRPV1 channel phosphorylation in 
the skin of the hind paw, and activation of ERK1/2 in the 
dorsal horns of the spinal cord in mice subjected to 
intraplantar injection of formalin preceded by kisspeptin or 
vehicle. Immunoblot analysis with anti-phosphorylated 
TRPV1 antibodies showed a single band at the expected 
molecular size of 95 kDa. We observed that in mice 
pretreated with vehicle, intraplantar injection of formalin 
slightly increased the levels of phosphorylated TRPV1 in 
the ipsilateral hind  paw as compared to naïve mice. This 
effect was largely amplified in mice pretreated with 
215 
 
kisspeptin (3 nmol/5 μl, 15 min prior to formalin injection) 
(Fig. 5). Activation of the mitogen activated protein kinase 
(MAPK) pathway was examined by immunohistochemical 
analysis of phosphorylated ERK1/2 in the dorsal horns of 
the spinal cord after intraplantar injection of formalin 
preceded by vehicle or kisspeptin. Formalin injection 
preceded by vehicle slightly enhanced phosphorylated 
ERK1/2 immunostaining in the dorsal horn ipsilateral to 
the injection side as compared to the contralateral dorsal 
horn or the dorsal horns of naïve mice (Fig. 6). 
Pretreatment with kisspeptin (3 nmol/μl) dramatically 
enhanced the expression of phosphorylated ERK1/2 in the 
ipsilateral dorsal horn (Fig. 6). 
 
Discussion 
These data offer the first demonstration that kisspeptin, a 
peptide known for its role in the regulation of the 
hypothalamic-pituitary-gonadal axis, lowers pain 
threshold and enhances nocifensive behavior in mice. 
Immunohistochemical analysis showed the presence of the 
kisspeptin receptor, GPR54, in peripheral sensory fibers, a 
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finding that is consistent with the detection of  GPR54 
mRNA and protein in DRG neurons [11, 12]. The lack of 
staining in GPR54 KO mice indicates that GPR54 is present 
in peripheral nociceptors explaining the hyperalgesia 
caused by intraplantar injection of kisspeptin in the hot 
plate and formalin test. We wish to highlight that 
intraplantar kisspeptin induced only a small nocifensive 
response on its own, suggesting that a main action of 
kisspeptin is to amplify pain sensitivity in response to 
noxious stimuli. Intraplantar injection of the GPR54 
antagonist, p234, caused a robust analgesia in the formalin 
test, suggesting that endogenous kisspeptin acts 
extracellularly to activate GPR54 receptors during 
inflammatory pain. Kisspeptin is present in DRG neurons, 
where it co-localizes with isolectin B4 and calcitonin gene-
related peptide, and its expression is up-regulated by 
chronic inflammatory pain [12]. It is likely that kisspeptin 
is released from peripheral nociceptors in response to 
noxious stimuli, therefore behaving as an 
autocrine/paracrine factor to promote peripheral 
nociceptive sensitization. 
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Whether other cells can produce and secrete kisspeptin 
during inflammation is unknown at present. 
Phosphorylation of the TRPV1 ion channel is a key event in 
mechanisms of peripheral nociceptive sensitization [20-22]. 
The TRPV1 receptor can be phosphorylated by multiple 
protein kinases, including protein kinase A, protein kinase 
C (PKC), calcium/calmodulin-dependent protein kinase II, 
and SRC [23-34]. In, particular, PKC phosphorylates 
TRPV1 at Ser-502 and Ser-800, thus amplifying ion channel 
activity [31, 35-37]. Intraplantar kisspeptin caused a robust 
increase in (Ser800)-TRPV1 phosphorylation, an effect that 
was likely mediated by the activation of the GPR54 
receptor, with ensuing stimulation of inositol phospholipid 
hydrolysis, diacylglycerol formation, and PKC activation 
[2, 8]. Thus, kisspeptin might act similarly to other 
hyperalgesic molecules that activate Gq-coupled receptors 
and phosphorylate TRPV1 channels in peripheral 
nociceptors, such as bradykinin, group-I mGlu receptor 
agonists, P2Y2 receptor agonists, EP1 receptor, and 
prokineticin [28, 38-48]. Hyperalgesia by kisspeptin and 
analgesia by p234 were also seen in the second phase of the 
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formalin test, which reflects the development of central 
nociceptive sensitization in the dorsal horns of the spinal 
cord [17, 18]. Central nociceptive sensitization is mediated 
by a series of mechanisms that ultimately lead to an 
enhancement of excitatory transmission at the synapses 
between primary afferent fibers and second order sensory 
neurons in the dorsal horns of the spinal cord [24]. The 
relevance of the MAPK pathway in the development of 
central sensitization has been highlighted in a recent 
review [48]. Intraplantar injection of formalin is known to 
induce a rapid phosphorylation of ERK1/2 in the spinal 
cord, which has been causally related to the increase in 
nocifensive behavior seen in the second phase of the 
formalin test [49]. Pharmacological activation of mGlu1 
and mGlu5 receptors, which also couple to the Gq protein 
just like GPR54 [50], can also enhance ERK1/2 
phosphorylation in the spinal cord [51]. Activation of 
GPR54 by kisspeptin has been shown to stimulate the 
ERK/MAPK pathway both in recombinant expression 
systems and hypothalamic explants [52, 53]. Intraplantar 
injection of kisspeptin markedly amplified ERK1/2 
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phosphorylation induced by formalin in the ipsilateral 
dorsal horn, evidence that nicely supports the behavioral 
data obtained with kisspeptin in the second phase of the 
formalin test. Interestingly, kisspeptin retained the 
hyperalgesic activity (and p234 the analgesic activity) 
when injected by the intrathecal route. Thus, it is likely that 
the modulation of pain sensitivity by GPR54 extends 
beyond  10 peripheral nociceptors. Effects of kisspeptin on 
different receptors cannot be  excluded. In particular  it has 
been reported that kisspeptin can also bind neuropeptide 
FF (NPFF) receptors [54]. However  in our hands 
intrathecal injection of kisspeptin lowers pain threshold, 
whereas intrathecal injection of NPFF is known to cause 
analgesia [55], thus the effect of kisspeptin in the spinal 
cord is likely mediated by the activation of the GPR54 
receptor excluding an interaction of kisspeptin with NPFF 
receptors. The presence of GPR54 receptor in the amygdala 
[56] may suggest that kisspeptin acts also at higher brain 
centers that control the affective components of pain and 
contributes to the top-down regulation of pain threshold. 
 
220 
 
 
Conclusions 
In conclusion, our data disclose a new aspect in the 
physiology of kisspeptin and suggest that peripheral 
GPR54 receptor antagonists (lacking potential 
hypothalamic side effects) can be developed as new drugs 
for the treatment of inflammatory pain. In addition, it will 
be interesting to explore whether individuals with  
hypogonadotropic hypogonadism due to inactivating 
mutations of GPR54 show alterations in the sensitivity to 
pain. 
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Figures 
  
 
 
 
 
Figure 1 – Immunostaining for the kisspeptin receptor, GPR54, 
in the mouse skin of GPR54 WT and KO mice. Representative 
immunostaining showing the specificity of the GPR54 antibody 
in the peripheral nerve endings of the mouse skin of GPR54+/+ 
mice (left panel). No mmunostaining is observed in GPR54-/- 
mice (right panel). Scale bar 100 μm. The insert shows an 
immunopositive fiber at higher magnification (scale bar = 20 
μm). 
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Figure 2 - Double immunofluorescent staining for the 
kisspeptin receptor, GPR54, and PGP9.5 in the mouse skin. 
Immunofluorescent staining of PGP9.5 and GPR54 is shown in 
(A) and (B), respectively. Coimmunolocalization is shown in (C) 
(see arrowheads). Scale bar 20 μm. 
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Figure 3 – Intraplantar injection of kisspeptin lowers pain 
threshold in the hot plate. The nocifensive response to 
intraplantar injection of kisspeptin (3 nmol/5 μl) in naïve mice is 
shown in (A). Data are means ± S.E.M of 6 mice, and refer to the 
number of sec spent in licking behavior in the first 5 min 
following injection. *p<0.05 (Student’s t test) vs. mice injected 
with vehicle. Data obtained in the hot plate test are shown in (B). 
For each animal, the percentage maximum possible effect 
(%MPE) was calculated using the following formula: [(post-drug 
latency) - (pre-drug latency)/(cutoff time) - (pre-drug latency)] x 
100. Data are means ± S.E.M. of 6 to 8 mice. *p<0.05, two-way 
ANOVA followed by Fisher’s post hoc test. PWL, Paw-
withdrawal latency. 
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Figure 4 – Effect of intraplantar or intrathecal injection of 
kisspeptin or the GPR54 antagonist, p234, in the formalin test. 
Data obtained with intraplantar (i.pl.) injection of kisspeptin (1 or 
3 nmol/5 μl) or p234 (0.01 or 0.1 nmol /5 μl) on the first (0-10 
min) and second (15-45 min) phases of the formalin test are 
shown in (A) and (B), respectively. Drugs were injected 15 min 
prior to the intraplantar injection of formalin. Data obtained with 
intrathecal (i.t.) injection of kisspeptin (0.5 or 1 nmol /3 μl) or 
p234 (0.1 or 1 nmol/3 μl) are shown in (C) and (D), respectively. 
Data are means + S.E.M. of 8-12 mice per group. *p<0.05 vs. the 
respective groups of mice injected with vehicle (one-way 
ANOVA followed by Fisher’s post hoc test). 
225 
 
 
Figure 5 – Intraplantar injection of kisspeptin amplified the 
increase in TRPV1 phosphorylation in the skin of mice treated 
with formalin. A representative immunoblot of (Ser800)-
phosphorylated TRPV1 in the skin of naïve mice and mice 
injected with formalin in the Absence or presence of kisspeptin (3 
nmol/5 μl) is shown in (A). Densitometric analysis is shown in 
(B), where values are means + S.E.M. of 4 determinations. 
*p<0.05 vs. naïve mice, #p<0.05 or vs. mice treated with formalin 
alone (one-way ANOVA followed by Fisher’s post hoc test). 
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Figure 6 – Intraplantar injection of kisspeptin increased ERK phopshorylation 
in the ipsilateral dorsal horn of the spinal cord. (A) Immunohistochemical 
analysis of phosphorylated-ERK1/2 in the dorsal horns of the spinal cords of 
naïve mice and mice treated with formalin in the Absence or presence of 
kisspeptin (3 nmol/5 μl) is shown. Contra = contralateral; ipsi = ipsilateral. Scale 
bar = 50 μm. The insert shows an immunopositive neuron at higher 
magnification (scale bar = 10 μm). (B) Densitometric analysis of p-ERK 
immunoreactivity in the superficial laminae of the dorsal horn. *p< 0.05 vs. 
contralateral values; #p< 0.05 vs. formalin alone values (one-way ANOVA + 
Dunnett’s Multiple Comparison Test). 
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Chapter 10: Conclusions 
 
10.1 Neurophysiological and morphological assessment 
Combining clinical, neurophysiological and morphological 
techniques, it is possible to objectively measure all 
nociceptive and non-nociceptive  afferent systems (Aβ-, 
Aδ- and C-fibers) all over the body in each patient. 
Neurophysiological assessment of afferent function in 
patients with neuropathic pain  is essential to increase our 
knowledge of the underlying pain-generating mechanisms. 
Conventional neurophysiological tests, such as nerve 
conduction studies or somatosensory-evoked potentials   
are often difficult to be applied in patients  with some 
conditions (i.e trigeminal neuralgia or postherpetic 
neuralgia in thoracic areas); moreover, they are no able to 
investigate Aδ- and C- nociceptive fibres. In our studies we  
circumvented these two problems through the use of blink-
reflex recordings in facial pain syndromes,  and laser-
evoked potentials to assess nociceptive pathway . Altough 
LEPs activate myelinated Aδ- and unmyelinated C-fibers, 
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does not allow differentiating the Aδ-nerves from the C-
nerves in extratrigeminal areas. Moreover, laser stimuli 
activate the intraepidermal nociceptive terminals, rather 
than the nerve axons.  So, we applied an additional 
technique: skin biopsy to take morphological informations  
of intraepidermal unmyelinated fibers and to calculate 
their density. Punch skin biopsy is easy to do, minimally 
invasive, and optimal for follow-up. Although low density 
of IENF is no correlated with the presence of neuropathic 
pain, it offers biomarkers of peripheral nerve damage, 
since the severe loss of IENF correlates with a more severe 
and longer neuropathy. Moreover, as discussed  in the 
previous chapter (about kisspeptine), skin biopsy showed 
in cutaneous fibers  the presence of GPR54 receptors, that 
could be targeted by novel analgesic drugs in the treatment 
of  pain . Despite these advantages, it is available only in 
few research centres. Our group recommend its larger 
spreading. 
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10.2 Neuropathic pain phenotypes 
 Finally, we sought possible correlations between 
neurophysiological and morphological data and the 
various qualities of neuropathic pain as assessed by the 
NPSI. We found that LEP amplitude (in patients with 
painful neuropathy) correlated with spontaneous constant 
pain, leading to an underling damage of nociceptive axons 
. Ongoing pain could be due to the abnormal spontaneous 
hyperactivity of damaged nociceptive  fibres that have lost 
their intraepidermal terminals, as assessed by skin biopsy. 
We can not exclude the possibility that nociceptive 
pathway damage may provoke long-term changes in the 
central nervous system, including hyperactivity of the 
second order neurons of the nociceptive pathway (central 
sensitization), that may act as a current mechanism. 
 The delay in blink-reflex latency (i.e in patients with 
PHN),  nerve sensory conduction velocity (i.e in patients 
with carpal tunnel syndrome), and somato-sensory evoked 
potential latency (i.e in patients with multiple sclerosis) 
correlated with paroxysmal pain and abnormal sensations. 
Our findings suggest that  paroxysmal pain and abnormal 
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sensations reflect demyelination of non-nociceptive Aβ-
fibres. A pathologic process in demyelinated Aβ-fibers is 
involved in the generation of pain. This is the case, even 
though Aβ-fibers normally do not convey noxious 
information.  Consistently with previous animal studies 
describing spontaneous ectopic discharges recorded in Aβ-
fibers after nerve injuries [1-3], we suggest that paroxysmal 
pain is related to high frequency bursts generated in 
demyelinated Aβ-fibers. It is still unclear, however, 
whether the abnormal activity in Aβ-fibers is sufficient to 
provoke pain per se, whether it arises after ephaptic 
transmission to neighboring C-fibers, or through a 
transmission to central multireceptive neurons (wide 
dynamic range neurons) [4]. 
While NCS data did not differ between patients with and 
without allodynia,  LEP amplitude was higher in patients 
with allodynia than in those without. We  argue against a 
role of Aβ-fibres and central sensitization as the main 
mechanism for the development of allodynia in distal 
symmetric polyneuropathy.  Our  findings suggest, though 
do not prove, that provoked pain arises through still intact, 
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and sensitized nociceptive terminals. The partially 
preserved LEPs in patients with allodynia suggests that 
this type of pain might be related to the abnormal 
reduction of mechanical threshold of nociceptive terminals 
(peripheral sensitization). 
We provided a clear evidence that neuropathic pain has 
different phenotypes, which very likely arise through a 
variety of distinct pathophysiological mechanisms.  Pain 
should be classified and treated on mechanism-based 
grounds. Distinct neuropathic signs and symptoms are 
generated by abnormalities of specific primary afferent 
neurons (Aβ- vs. Aδ- and C-fibers).  Moreover, sensory 
signs and symptoms are very heterogeneous in patients 
suffering from an identical disease entity. The different 
somatosensory abnormalities  are considered to reflect 
different underlying pain-generating mechanisms. For this 
reason, the individual pattern of somatosensory 
abnormalities at the affected body area,  may be a 
promising biomarker for the operating mechanisms.  A 
comparison of objective neurophysiological and 
morphogical tests  with the clinical phenotype is thus a 
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particularly appropriate approach to unravel the 
underlying pathophysiology, leading to detect a specific 
and positive treatment . Perhaps it is possible to extend the 
data analysis and correlate the neuropathic pain phenotype 
and  the sensory  neurophysiological and morphological 
testing   with the  treatment response obtained with certain 
drug classes. This effort would be invaluable for our 
understanding of pain. 
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